<SEC-DOCUMENT>0001193125-17-362903.txt : 20171206
<SEC-HEADER>0001193125-17-362903.hdr.sgml : 20171206
<ACCEPTANCE-DATETIME>20171206170303
ACCESSION NUMBER:		0001193125-17-362903
CONFORMED SUBMISSION TYPE:	424B2
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20171206
DATE AS OF CHANGE:		20171206

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			HERON THERAPEUTICS, INC. /DE/
		CENTRAL INDEX KEY:			0000818033
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				942875566
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		424B2
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-219172
		FILM NUMBER:		171242868

	BUSINESS ADDRESS:	
		STREET 1:		4242 CAMPUS POINT COURT, SUITE 200
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92121
		BUSINESS PHONE:		6503662626

	MAIL ADDRESS:	
		STREET 1:		4242 CAMPUS POINT COURT, SUITE 200
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92121

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	AP PHARMA INC /DE/
		DATE OF NAME CHANGE:	20010511

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ADVANCED POLYMER SYSTEMS INC /DE/
		DATE OF NAME CHANGE:	19920703
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B2
<SEQUENCE>1
<FILENAME>d504779d424b2.htm
<DESCRIPTION>424B2
<TEXT>
<HTML><HEAD>
<TITLE>424B2</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Filed pursuant to Rule 424(b)(2) <BR> Registration Statement No. 333-219172 <BR> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CALCULATION OF REGISTRATION FEE </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="36%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="15%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="15%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="15%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="15%"></TD></TR>


<TR STYLE="font-size:1px; ">
<TD COLSPAN="9" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"><B>Title of Securities to be Registered</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Amount</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>to be</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Registered</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Proposed</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Maximum</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Offering
Price</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Per Share</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Proposed</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Maximum</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Aggregate</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Offering&nbsp;Price</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Amount&nbsp;of</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Registration&nbsp;Fee<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></B></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Common&nbsp;Stock,&nbsp;$0.01&nbsp;par&nbsp;value&nbsp;per&nbsp;share</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000">11,129,032</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000">$16.67</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000">$185,520,964</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000">$23,097.36</TD></TR>
<TR STYLE="font-size:1px; ">
<TD COLSPAN="9" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1px; ">
<TD COLSPAN="9" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
</TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">Estimated in accordance with Rule&nbsp;457(c) solely for purposes of calculating the registration fee. The maximum price per share and the maximum aggregate offering price are based on the average of the high and low
sale price of the registrant&#146;s common stock as reported on The NASDAQ Capital Market on November&nbsp;28, 2017. </TD></TR></TABLE>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>PROSPECTUS&nbsp;SUPPLEMENT
</U></B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>(To Prospectus dated July&nbsp;6, 2017) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>9,677,419&nbsp;Shares </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g504779g04j69.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Common Stock </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are offering
9,677,419&nbsp;shares of our common stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our common stock is listed on The NASDAQ Capital Market under the symbol &#147;HRTX.&#148; On
December&nbsp;4,&nbsp;2017, the last reported sale price per share of our common stock was $17.15 per share. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman"><B>Investing in our securities involves
certain risks. See &#147;<A HREF="#supptoc504779_18">Risk Factors</A>&#148; beginning on Page&nbsp;S-10 of this prospectus supplement and in the accompanying prospectus, and in the other documents that are incorporated by reference and any related
free writing prospectus, for certain risks you should consider. You should read the entire prospectus supplement and the accompanying prospectus, including any information incorporated by reference, carefully before you make your investment
decision. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The underwriter has agreed to purchase shares of our common stock from us at a price of $14.75 per share, which will result
in approximately $142.7&nbsp;million of proceeds, before expenses, to us. The underwriter may offer the shares of common stock from time to time to purchasers directly or through agents, or through brokers in brokerage transactions on The NASDAQ
Capital Market, or to dealers in negotiated transactions, or in a combination of such methods of sale or otherwise, at a fixed price or prices, which may be changed, or at market prices prevailing at the time of sale, at prices related to such
prevailing market prices or at negotiated prices. See &#147;Underwriting&#148;. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The underwriter may also exercise its option to purchase
up to an additional 1,451,613&nbsp;shares of common stock from us, at a price of $14.75 per share, for 30 days after the date of this prospectus supplement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Neither the Securities and Exchange Commission nor any other regulatory body has approved or disapproved of these securities or passed upon
the accuracy or adequacy of this prospectus supplement or the accompanying prospectus. Any representation to the contrary is a criminal offense. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The shares will be ready for delivery on or about December&nbsp;7, 2017. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>Sole Book-Running Manager </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman" ALIGN="center"><B>Cantor </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Prospectus
Supplement dated December&nbsp;4, 2017. </B></P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc"></A>TABLE OF CONTENTS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="93%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>PAGE</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>PROSPECTUS SUPPLEMENT</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supptoc504779_14">ABOUT THIS PROSPECTUS SUPPLEMENT</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">S-1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supptoc504779_15">NOTE REGARDING FORWARD-LOOKING STATEMENTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">S-2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supptoc504779_16">PROSPECTUS SUMMARY</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">S-4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supptoc504779_17">THE OFFERING</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">S-9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supptoc504779_18">RISK FACTORS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">S-10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supptoc504779_19">USE OF PROCEEDS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">S-11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supptoc504779_20">UNDERWRITING</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">S-12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supptoc504779_21">LEGAL MATTERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">S-20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supptoc504779_22">EXPERTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">S-21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supptoc504779_23">INFORMATION INCORPORATED BY REFERENCE</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">S-22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supptoc504779_24">WHERE YOU CAN FIND ADDITIONAL INFORMATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">S-23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>PROSPECTUS</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc504779_1">ABOUT THIS PROSPECTUS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc504779_2">NOTE REGARDING FORWARD-LOOKING STATEMENTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc504779_3">ABOUT THE COMPANY</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc504779_4">RISK FACTORS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc504779_5">USE OF PROCEEDS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc504779_6">RATIO OF EARNINGS TO FIXED CHARGES</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc504779_7">DESCRIPTION OF SECURITIES</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc504779_8">SELLING STOCKHOLDERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc504779_9">PLAN OF DISTRIBUTION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc504779_10">EXPERTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc504779_11">LEGAL MATTERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc504779_12">INFORMATION INCORPORATED BY REFERENCE</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc504779_13">WHERE YOU CAN FIND ADDITIONAL INFORMATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You should rely only on the information contained in this prospectus supplement and the
accompanying prospectus, including any information incorporated by reference, and in any free writing prospectus that we have authorized for use in connection with this offering. We have not, and the underwriter has not, authorized anyone to provide
you with different information. If anyone provides you with different or inconsistent information, you should not rely on it. You should not assume that the information contained in this prospectus supplement and the accompanying prospectus, or in
any free writing prospectus that we have authorized for use in connection with this offering, is accurate as of any date other that the date of those respective documents, or that information contained in any document incorporated by reference is
accurate as of any date other than the date of the document incorporated by reference. Our business, financial condition, results of operations and prospects may have changed since those dates. We are not, and the underwriter is not, making offers
to sell these securities in any jurisdiction in which an offer or solicitation is not authorized or permitted or in which the person making such offer or solicitation is not qualified to do so or to any person to whom it is unlawful to make such an
offer or solicitation. You should read this prospectus supplement, the accompanying prospectus, including any information incorporated by reference, and any free writing prospectus that we have authorized for use in connection with this offering, in
their entirety before making an investment decision. You should also read and consider the information in the documents to which we have referred you in the sections entitled &#147;Where You Can Find Additional Information&#148; and
&#147;Information Incorporated by Reference.&#148; </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supptoc504779_14"></A>ABOUT THIS PROSPECTUS SUPPLEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus supplement and the accompanying prospectus form part of a registration statement on Form&nbsp;S-3 that we filed with the
Securities and Exchange Commission (the &#147;SEC&#148;) using a shelf registration process. This document contains two parts. The first part consists of this prospectus supplement, which provides you with specific information about this offering.
The second part, the accompanying prospectus, provides more general information, some of which may not apply to this offering. Generally, when we refer only to the &#147;prospectus,&#148; we are referring to both parts combined. This prospectus
supplement may add, update or change information contained in the accompanying prospectus. To the extent that any statement we make in this prospectus supplement is inconsistent with statements made in the accompanying prospectus or any documents
incorporated by reference, the statements made in this prospectus supplement will be deemed to modify or supersede those made in the accompanying prospectus, including the documents incorporated by reference therein. Information in any document we
subsequently file that is incorporated by reference shall modify or supersede the information in the prospectus supplement, the accompanying prospectus and documents incorporated by reference prior to such subsequent filing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In this prospectus supplement, &#147;Heron,&#148; the &#147;Company,&#148; &#147;we,&#148; &#147;us,&#148; and &#147;our&#148; and similar
terms refer to Heron Therapeutics, Inc. References to our &#147;common stock&#148; refer to the common stock of Heron Therapeutics, Inc. Heron Therapeutics<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>, the Heron logo, SUSTOL<SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP>, CINVANTI<SUP STYLE="font-size:85%; vertical-align:top">&#153;</SUP>and Biochronomer<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> are our trademarks. All other trademarks appearing
or incorporated by reference into this prospectus supplement are the property of their respective owners. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All references in this
prospectus supplement to our financial statements include, unless the context indicates otherwise, the related notes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The industry and
market data and other statistical information contained in this prospectus supplement, the accompanying prospectus and the documents we incorporate by reference are based on management&#146;s own estimates, independent publications, and reports by
market research firms or other published independent sources, and, in each case, are believed by management to be reasonable estimates. Although we believe these sources are reliable, we have not independently verified the information. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-1 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supptoc504779_15"></A>NOTE REGARDING FORWARD LOOKING STATEMENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>This prospectus supplement contains forward-looking statements within the meaning of the federal securities laws. We make such
forward-looking statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. You can identify forward-looking statements by the use of the words &#147;believe,&#148;
&#147;expect,&#148; &#147;anticipate,&#148; &#147;intend,&#148; &#147;estimate,&#148; &#147;project,&#148; &#147;will,&#148; &#147;should,&#148; &#147;may,&#148; &#147;plan,&#148; &#147;assume&#148; and other expressions that predict or indicate
future events and trends and which do not relate to historical matters. You should not rely on forward-looking statements, because they involve known and unknown risks, uncertainties and other factors, some of which are beyond our control. These
risks, uncertainties and other factors may cause our actual results, performance or achievements to be materially different from the anticipated future results, performance or achievements expressed or implied by the forward-looking statements.
</I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Factors that might cause these differences include the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our ability to successfully commercialize, market and achieve market acceptance of SUSTOL<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> (granisetron) extended-release injection (&#147;SUSTOL&#148;),
CINVANTI&#153; (aprepitant) injectable emulsion (&#147;CINVANTI&#148;) and future product candidates, including our positioning relative to competing products; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">estimates of the outcome of the commercial launch of CINVANTI; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">whether the HTX-011 Phase 2 study results are indicative of the results in future studies; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the timing of completion and results of the Phase 3 studies of HTX-011; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the timing of the New Drug Application (&#147;NDA&#148;) submission to the U.S. Food and Drug Administration (&#147;FDA&#148;) for HTX-011 and potential regulatory approval for and commercial launch of HTX-011;
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the potential market opportunities for SUSTOL, CINVANTI and HTX-011; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our competitors&#146; activities, including decisions as to the timing of competing product launches, generic entrants, pricing and discounting; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">whether safety and efficacy results of our clinical trials and other required tests for approval of our product candidates provide data to warrant progression of clinical trials, potential regulatory approval or further
development of any of our product candidates; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our ability to develop, acquire and advance product candidates into, and successfully complete, clinical studies, and our ability to submit for and obtain regulatory approval for product candidates, in our anticipated
timing, or at all; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our ability to meet the postmarketing study requirements within the FDA&#146;s mandated timelines and to obtain favorable results and comply with standard postmarketing requirements including U.S. federal advertising
and promotion laws, federal and state anti-fraud and abuse laws, healthcare information privacy and security laws, safety information, safety surveillance, and disclosure of payments or other transfers of value to healthcare professionals and
entities for SUSTOL, CINVANTI or any of our product candidates; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our ability to successfully develop and achieve regulatory approval for other future product candidates utilizing our proprietary Biochronomer<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> sustained-release
drug delivery technology (&#147;Biochronomer technology&#148;); </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our ability to establish key collaborations and vendor relationships for our products and any other future product candidates; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our ability to successfully develop and commercialize any technology that we may in-license or products we may acquire; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-2 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">unanticipated delays due to manufacturing difficulties, supply constraints or changes in the regulatory environment; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our ability to successfully operate in non-U.S. jurisdictions in which we may choose to do business, including compliance with applicable regulatory requirements and laws; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">uncertainties associated with obtaining and enforcing patents to protect our products, and our ability to successfully defend ourselves against unforeseen third-party infringement claims; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our estimates regarding our capital requirements; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our ability to obtain additional financing and raise capital as necessary to fund operations or pursue business opportunities. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any forward-looking statements in this prospectus supplement reflect our current views with respect to future events or to our future
financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or
implied by these forward-looking statements. Factors that may cause actual results to differ materially from current expectations include, among other things, those listed under the section entitled &#147;Risk Factors&#148; in this prospectus, the
accompanying prospectus supplement and elsewhere in documents incorporated by reference herein. You should carefully review all of these factors. Given these uncertainties, you should not place undue reliance on these forward-looking statements.
These forward-looking statements were based on information, plans and estimates as of the date of this prospectus, and except as required by law, we assume no obligation to update any forward-looking statements to reflect changes in underlying
assumptions or factors, new information, future events or other changes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus supplement may also contain estimates,
projections and other information concerning our industry, our business, and the markets for certain diseases, including data regarding the estimated size of those markets. Information that is based on estimates, forecasts, projections, market
research or similar methodologies is inherently subject to uncertainties and actual events or circumstances may differ materially from events and circumstances reflected in this information. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-3 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supptoc504779_16"></A>PROSPECTUS SUMMARY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>The following summary of our business highlights certain of the information contained elsewhere in or incorporated by reference into this
prospectus supplement and the accompanying prospectus. Because this is only a summary, however, it does not contain all of the information that may be important to you. You should carefully read this prospectus supplement and the accompanying
prospectus, including the documents incorporated by reference, which are described under &#147;Where You Can Find Additional Information&#148; and &#147;Information Incorporated By Reference&#148; in the accompanying prospectus. In particular, you
should carefully consider the matters discussed in the section of this prospectus supplement titled &#147;Risk Factors&#148; and in the accompanying prospectus and periodic reports incorporated herein by reference. </I></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Company </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are a commercial-stage
biotechnology company focused on improving the lives of patients by developing best-in-class treatments that address some of the most important unmet patient needs. We are developing novel, patient-focused solutions that apply our innovative science
and technologies to already approved pharmacological agents for patients suffering from cancer or pain. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On August&nbsp;9, 2016, our first
commercial product, SUSTOL, was approved by the FDA. We developed SUSTOL for the prevention of chemotherapy-induced nausea and vomiting (&#147;CINV&#148;). SUSTOL is indicated, in combination with other antiemetics, in adults for the prevention of
acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (&#147;MEC&#148;) or anthracycline and cyclophosphamide (&#147;AC&#148;) combination chemotherapy regimens. We commenced
commercial sales of SUSTOL in October 2016. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On November&nbsp;9, 2017, our second commercial product, CINVANTI, an intravenous formulation
of the neurokinin-1 (&#147;NK<SUB STYLE="font-size:85%; vertical-align:bottom">1</SUB>&#148;) receptor antagonist aprepitant, was approved by the FDA. We developed CINVANTI for the prevention of CINV as an adjunct to other antiemetic agents.
CINVANTI, in combination with other antiemetic agents, is indicated in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy (&#147;HEC&#148;),
including high-dose cisplatin, and nausea and vomiting associated with initial and repeat courses of MEC. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We also have an investigational
pharmaceutical product in development for patients suffering from postoperative pain. HTX-011 is a long-acting formulation of the local anesthetic bupivacaine in a fixed-dose combination with the anti-inflammatory meloxicam for the prevention of
postoperative pain. By delivering sustained levels of both a potent anesthetic and an anti-inflammatory agent directly to the site of tissue injury, HTX-011 was designed to provide superior pain relief while potentially reducing the need for
systemically administered pain medications such as opioids, which carry the risk of harmful side effects, abuse and addiction. The Phase 2 development program for HTX-011 was designed to target the many patients undergoing a wide range of surgeries
who experience significant postoperative pain. Following an End-of-Phase 2 meeting with the FDA, we initiated our Phase 3 program, which we anticipate completing in the first half of 2018. We expect to file an NDA for HTX-011 in 2018. We have been
granted Fast Track designation for HTX-011 by the FDA for local administration into the surgical site to reduce postoperative pain and the need for opioid analgesics for 72 hours. Fast Track designation is intended to facilitate the development and
expedite the review of new therapies to treat serious conditions with unmet medical needs by providing sponsors with the opportunity for frequent interactions with the FDA. </P>
 <P STYLE="margin-top:0pt;margin-bottom:0pt; font-size:8pt">&nbsp;</P></div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-4 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>CINV Product Portfolio </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>SUSTOL </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SUSTOL is our first commercial
product. SUSTOL was approved by the FDA on August&nbsp;9, 2016, and we commenced commercial sales in the U.S. in October 2016. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SUSTOL is
indicated in combination with other antiemetics in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of MEC or AC combination chemotherapy regimens. SUSTOL is an extended-release,
injectable 5-hydroxytryptamine type 3 (&#147;5-HT<SUB STYLE="font-size:85%; vertical-align:bottom">3</SUB>&#148;) receptor antagonist that utilizes our Biochronomer technology to maintain therapeutic levels of granisetron for 5 days. The SUSTOL
global Phase 3 development program was comprised of two, large, guideline-based clinical trials that evaluated efficacy and safety in more than 2,000 patients with cancer. The efficacy of SUSTOL in preventing nausea and vomiting was evaluated in
both the acute phase (day 1 following chemotherapy) and the delayed phase (days 2-5 following chemotherapy). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SUSTOL is the first
extended-release 5-HT<SUB STYLE="font-size:85%; vertical-align:bottom">3</SUB> receptor antagonist approved for the prevention of acute and delayed nausea and vomiting associated with both MEC and AC combination chemotherapy regimens. A standard of
care in the treatment of breast cancer and other cancer types, AC regimens are among the most commonly prescribed HEC regimens as defined by both the National Comprehensive Cancer Network (&#147;NCCN&#148;) and the American Society of Clinical
Oncology. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In February 2017, the NCCN included SUSTOL as a part of its NCCN Clinical Practice Guidelines in Oncology for Antiemesis
Version 1.2017. The NCCN has given SUSTOL a Category 1 recommendation, the highest level category of evidence and consensus, for use in the prevention of acute and delayed CINV in patients receiving HEC or MEC regimens. The guidelines now identify
SUSTOL as a &#147;preferred&#148; agent for preventing CINV following MEC. Further, the guidelines highlight the unique, extended-release formulation of SUSTOL. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>CINVANTI </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">CINVANTI, an intravenous
formulation of the NK<SUB STYLE="font-size:85%; vertical-align:bottom">1</SUB> receptor antagonist aprepitant, was approved by the FDA on November&nbsp;9, 2017. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We developed CINVANTI for the prevention of CINV as an adjunct to other antiemetic agents. CINVANTI, in combination with other antiemetic
agents, is indicated in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of HEC, including high-dose cisplatin, and nausea and vomiting associated with initial and repeat courses of MEC.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">CINVANTI is a proprietary, intravenous formulation of aprepitant, an NK<SUB STYLE="font-size:85%; vertical-align:bottom">1</SUB> receptor
antagonist for the prevention of CINV. NK<SUB STYLE="font-size:85%; vertical-align:bottom">1</SUB> receptor antagonists are typically used in combination with 5-HT<SUB STYLE="font-size:85%; vertical-align:bottom">3</SUB> receptor antagonists. The
only other injectable NK<SUB STYLE="font-size:85%; vertical-align:bottom">1</SUB> receptor antagonist currently approved in the U.S. for both acute and delayed CINV, EMEND<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> IV (fosaprepitant),
contains polysorbate 80, a synthetic surfactant, which may increase the risk of hypersensitivity reactions and other infusion site reactions. Our formulation for CINVANTI does not contain a synthetic surfactant. Our CINVANTI data has demonstrated
the bioequivalence of CINVANTI to EMEND IV for Injection, supporting its efficacy for the prevention of both acute and delayed CINV with both MEC and HEC. Results also showed CINVANTI was better tolerated in healthy volunteers than EMEND IV for
Injection, with significantly fewer adverse events reported with CINVANTI. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Pain Management Product Portfolio </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>HTX-011 </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">HTX-011, which utilizes our
Biochronomer technology, is a long-acting formulation of the local anesthetic bupivacaine in a fixed-dose combination with the anti-inflammatory meloxicam for the prevention of </P>
 <P STYLE="margin-top:0pt;margin-bottom:0pt; font-size:8pt">&nbsp;</P></div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-5 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
postoperative pain. By delivering sustained levels of both a potent anesthetic and an anti-inflammatory agent directly to the site of tissue injury, HTX-011 was designed to provide superior pain
relief while potentially reducing the need for systemically administered pain medications such as opioids, which carry the risk of harmful side effects, abuse and addiction. The Phase 2 development program for HTX-011 was designed to target the many
patients undergoing a wide range of surgeries who experience significant postoperative pain. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In October 2017, we announced that we have
been granted Fast Track designation for HTX-011 by the FDA for local administration into the surgical site to reduce postoperative pain and the need for opioid analgesics for 72 hours. Fast Track designation is intended to facilitate the development
and expedite the review of new therapies to treat serious conditions with unmet medical needs by providing sponsors with the opportunity for frequent interactions with the FDA. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In August 2017, we announced the positive outcome of a recent End-of-Phase 2 meeting with the FDA. General agreement was reached with the FDA
on the design and key elements for HTX-011&#146;s Phase 3 program that will be required to support an NDA. The program includes two pivotal Phase 3 efficacy studies in bunionectomy and hernia repair, representing a bony model and a soft tissue
model, respectively. Our Phase 3 program is designed to achieve a broad indication for the reduction in postoperative pain for 72 hours following surgery. The primary endpoints of the Phase 3 efficacy studies will be the difference in mean area
under the curve (&#147;AUC&#148;) of pain intensity scores through 72 hours compared with placebo. The first key secondary endpoints will be the difference in mean AUC of pain intensity scores through 72 hours compared with bupivacaine. Additional
key secondary endpoints measuring reduction in opioid use and proportion of subjects who are opioid-free are included to support an opioid-sparing claim. In addition to the Phase 3 efficacy studies, approximately 200 additional patients will be
enrolled in studies looking at pharmacokinetics, pharmacodynamics and safety in other surgical models to meet the target patient numbers established by the FDA and to provide further evidence of the broad utility of HTX-011 across multiple surgical
models. Importantly, the FDA noted that, beyond the agreed-upon Phase 3 program, no additional clinical work is needed to meet the &#147;Combination Rule&#148; for fixed-dose combination products. We have initiated our Phase 3 program, which we
anticipate completing in the first half of 2018. We expect to file an NDA for HTX-011 in 2018. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In August 2017, we reported final Phase 2
study results using the doses, route of administration and statistical methodology that will be used in the Phase 3 studies. These results indicate that HTX-011 has consistently demonstrated superiority over placebo and bupivacaine, the current
standard of care, in all surgical models evaluated. HTX-011 has been generally well tolerated in the Phase 2 program, which has involved more than 600 administrations of HTX-011. The most frequent treatment-related adverse events with HTX-011
reported have been nausea and vomiting, which occurred at similar rates in both bupivacaine control and placebo control patients. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Bunionectomy &#150;
Study 208 </U></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In August 2017, we reported final Phase 2 study results from Study 208 using the doses, route of administration and
statistical methodology that will be used in the Phase 3 studies. These results indicate that HTX-011 has consistently demonstrated superiority over placebo and bupivacaine, the current standard of care, in patients undergoing bunionectomy. These
results were as follows: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">60 mg of HTX-011 reduced pain through 72 hours significantly better than placebo (p=0.0003) and bupivacaine 50 mg (p=0.0166); </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">HTX-011&#146;s pain reduction through 72 hours, as compared to placebo, was 24 times greater than a similar dose of bupivacaine; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">60 mg of HTX-011 significantly reduced opioid consumption through 72 hours as compared to both placebo (p=0.0047) and bupivacaine (p=0.0382). </TD></TR></TABLE>
 <P STYLE="margin-top:0pt;margin-bottom:0pt; font-size:8pt">&nbsp;</P></div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-6 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Inguinal Hernia Repair &#150; Study 202 </U></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In August 2017, we reported final Phase 2 study results from Study 202 using the doses, route of administration and statistical methodology
that will be used in our Phase 3 studies. These results indicate that HTX-011 has consistently demonstrated superiority over placebo and bupivacaine, the current standard of care, in patients undergoing inguinal hernia repair. These results were as
follows: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">300 mg of HTX-011 reduced pain through 72 hours significantly better than placebo (p=0.0045) and bupivacaine 75 mg (p=0.0427); </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">HTX-011&#146;s pain reduction through 72 hours, as compared to placebo, was more than 4 times greater than bupivacaine; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">300 mg of HTX-011 reduced opioid consumption by 35.5% compared to placebo and by 26.7% compared to bupivacaine and significantly increased the proportion of patients who were opioid-free through 72 hours compared to
both placebo (p=0.0001) and bupivacaine (p=0.0108). </TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Abdominoplasty &#150; Study 203 </U></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In August 2017, we reported preliminary Phase 2 study results using the statistical methodology that will be used in the Phase 3 studies. These
results indicate that HTX-011 has consistently demonstrated superiority over placebo and bupivacaine, the current standard of care, in patients undergoing abdominoplasty. These results were as follows: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">400 mg of HTX-011 reduced pain through 72 hours significantly better than placebo (p=0.0041) and bupivacaine 100 mg (p=0.0399); </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">HTX-011&#146;s pain reduction through 72 hours, as compared to placebo, was more than 5 times greater than bupivacaine; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">400 mg of HTX-011 significantly reduced opioid consumption through 72 hours as compared to both placebo (p=0.0047) and bupivacaine (p=0.0161). </TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Biochronomer Technology </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our
proprietary Biochronomer technology is designed to deliver therapeutic levels of a wide range of otherwise short-acting pharmacological agents over a period from days to weeks with a single administration. Our Biochronomer technology consists of
bioerodible polymers that have been the subject of comprehensive animal and human toxicology studies that have shown evidence of the safety of the polymer. When administered, the polymers undergo controlled hydrolysis, resulting in a controlled,
sustained release of the pharmacological agent encapsulated within the Biochronomer-based composition. Furthermore, our Biochronomer technology is designed to permit more than one pharmacological agent to be incorporated, such that multimodal
therapy can be delivered with a single administration. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Corporate Information </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have executive offices located at 4242 Campus Point Court, Suite 200, San Diego, California 92121 and our telephone number is
(858)&nbsp;251-4400. Our Internet website address is<I> www.herontx.com.</I> We make our periodic and current reports available on our Internet website, free of charge, as soon as reasonably practicable after such material is electronically filed
with, or furnished to, the SEC. No portion of our website is incorporated by reference into this prospectus supplement. The Company files annual, quarterly and special reports, proxy statements and other information with the SEC. You may read and
copy any document filed by the Company at the SEC&#146;s Public Reference Room at 100 F Street, N.E., Washington, D.C. 20549. Please call the SEC at 1-800-</P>
 <P STYLE="margin-top:0pt;margin-bottom:0pt; font-size:8pt">&nbsp;</P></div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-7 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
SEC- 0330 for further information on the public reference room. The Company&#146;s filings with the SEC are also available to the public on the SEC&#146;s Internet web site at<I>
http://www.sec.gov</I>. Additional information regarding the Company, including our audited financial statements and descriptions of our business, is contained in the documents incorporated by reference in this prospectus supplement. See &#147;Where
You Can Find Additional Information&#148; and &#147;Information Incorporated by Reference&#148; in this prospectus supplement and the accompanying prospectus. Our common stock is listed on The NASDAQ Capital Market under the symbol
&#147;HRTX.&#148;</P>
 <P STYLE="margin-top:0pt;margin-bottom:0pt; font-size:8pt">&nbsp;</P></div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-8 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supptoc504779_17"></A>THE OFFERING </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Common Stock we are Offering Pursuant to this Prospectus Supplement </P></TD>
<TD>9,677,419&nbsp;shares </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Common Stock to be Outstanding after this Offering </P></TD>
<TD>64,178,997&nbsp;shares </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Option to Purchase Additional Shares </P></TD>
<TD>We have granted the underwriter an option for a period of 30 days from the date of this prospectus supplement to purchase up to 1,451,613 additional shares. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Use of Proceeds </P></TD>
<TD>We intend to use the net proceeds of this offering primarily for general corporate purposes, which include, but are not limited to, the continued commercialization and marketing of SUSTOL, the commercial launch of CINVANTI, funding our ongoing
and future clinical trials, including further Phase 2 studies and Phase 3 studies for HTX-011, preclinical development work, for general and administrative expenses, repayment of a portion of the Promissory Note held by Tang Capital Partners, LP,
which Promissory Note matures in August 2018 and bears interest at a rate of 8% per annum, or other product development activities. See &#147;Use of Proceeds.&#148; </TD></TR></TABLE>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">NASDAQ Capital Market Symbol </P></TD>
<TD>&#147;HRTX&#148; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Risk Factors </P></TD>
<TD>This investment involves a high degree of risk. You should read the &#147;Risk Factors&#148; section of this prospectus supplement and the accompanying prospectus and our most recent Annual Report on Form&nbsp;10-K and any subsequent Quarterly
Reports on Form 10-Q, incorporated by reference herein, for a discussion of factors to consider carefully before deciding to invest in shares of our common stock. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The number of shares of common stock shown above to be outstanding after this offering is based on the 54,501,578 shares outstanding as of
September&nbsp;30, 2017 and excludes: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">11,198,556 shares of our common stock subject to options outstanding as of September&nbsp;30, 2017 having a weighted average exercise price of $14.56 per share; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">7,348,570 shares of our common stock that have been reserved for issuance in connection with future grants under our Amended and Restated 2007&nbsp;Equity Plan (the &#147;2007&nbsp;Plan&#148;) as of September&nbsp;30,
2017; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">620,164 shares of our common stock that have been reserved for issuance upon exercise of outstanding warrants as of September&nbsp;30, 2017, having a weighted average exercise price of $0.49&nbsp;per share; and
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">7,864,983 shares of common stock issuable upon the conversion of outstanding principal due under outstanding secured convertible promissory notes outstanding as of September&nbsp;30, 2017. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the underwriter&#146;s option to purchase additional shares is exercised in full, we will issue and sell an additional
1,451,613&nbsp;shares of our common stock and will have 65,630,610&nbsp;shares outstanding after the offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except as otherwise noted,
all information in this prospectus supplement assumes no exercise of the underwriter&#146;s option to purchase additional shares. </P>
 <P STYLE="margin-top:0pt;margin-bottom:0pt; font-size:8pt">&nbsp;</P></div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-9 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supptoc504779_18"></A>RISK FACTORS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>An investment in our common stock involves a high degree of risk. Before deciding whether to invest in our common stock, you should
consider carefully the risks described below and discussed under the sections captioned &#147;Risk Factors&#148; contained in our Annual Report on Form 10-K for the year ended December&nbsp;31, 2016, and any subsequent Quarterly Reports on Form
10-Q, which are incorporated by reference herein in their entirety, together with other information contained in or incorporated by reference in this prospectus supplement and in any free writing prospectus that we have authorized for use in
connection with this offering. If any of these risks actually occurs, our business, financial condition, results of operations or prospects could be seriously harmed. This could cause the trading price of our common stock to decline, resulting in a
loss of all or part of your investment. </I></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Relating to this Offering </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We will have broad discretion in the use of the net proceeds to us from this offering; we may not use the offering proceeds that we receive effectively.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our management will have broad discretion in the application of the net proceeds to us from this offering, including for any of
the purposes described in the section entitled &#147;Use of Proceeds,&#148; and you will not have the opportunity as part of your investment decision to assess whether the net proceeds are being used appropriately. Because of the number and
variability of factors that will determine our use of the net proceeds to us from this offering, their ultimate use may vary from their currently intended use. The failure by our management to apply these funds effectively could harm our business.
Pending their use, we may invest the net proceeds to us from this offering in investment-grade, interest-bearing securities. These investments may not yield a favorable return to our stockholders. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-10 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supptoc504779_19"></A>USE OF PROCEEDS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We estimate that the net proceeds from the sale of the shares of common stock that we are offering will be approximately $142.7&nbsp;million,
or approximately $164.2&nbsp;million if the underwriter exercises in full its option to purchase up to 1,451,613 additional shares of common stock, after deducting the underwriting discounts and commissions, but before deducting estimated offering
expenses payable by us. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We intend to use the net proceeds from the sale of the shares of common stock offered hereby primarily for
general corporate purposes, which include, but are not limited to, the continued commercialization and marketing of SUSTOL, the commercial launch of CINVANTI, funding our ongoing and future clinical trials, including further Phase 2 studies and
Phase 3 studies for HTX-011, preclinical development work, for general and administrative expenses, repayment of a portion of the Promissory Note held by Tang Capital Partners, LP, which Promissory Note matures in August 2018 and bears interest at a
rate of 8% per annum, or other product development activities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pending the use of the net proceeds, we intend to invest the net proceeds
in short-term, interest-bearing, investment-grade securities. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-11 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supptoc504779_20"></A>UNDERWRITING </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have entered into an underwriting agreement with Cantor Fitzgerald&nbsp;&amp; Co. with respect to the shares of common stock being offered
hereby. Subject to the terms and conditions set forth in an underwriting agreement among us and the underwriter, the underwriter has agreed to purchase from us 9,677,419&nbsp;shares of our common stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to the terms and conditions set forth in the underwriting agreement, the underwriter has agreed to purchase all of the shares sold
under the underwriting agreement if any of these shares are purchased. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have agreed to indemnify the underwriter against certain
liabilities, including liabilities under the Securities Act of 1933, as amended, and to contribute to payments the underwriter may be required to make in respect of those liabilities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The underwriter is offering the shares, subject to prior sale, when, as and if issued to and accepted by it, subject to approval of legal
matters by its counsel, including the validity of the shares, and other conditions contained in the underwriting agreement, such as the receipt by the underwriter of officer&#146;s certificates and legal opinions. The underwriter reserves the right
to withdraw, cancel or modify offers to the public and to reject orders in whole or in part. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Commissions and Discounts. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The underwriter has agreed to purchase shares of our common stock from us at a price of $14.75 per share, which will result in approximately
$142.7&nbsp;million of proceeds, before expenses, to us. The underwriter may offer the shares of common stock from time to time to purchasers directly or through agents, or through brokers in brokerage transactions on The NASDAQ Capital Market, or
to dealers in negotiated transactions, or in a combination of such methods of sale or otherwise, at a fixed price or prices, which may be changed, or at market prices prevailing at the time of sale, at prices related to such prevailing market prices
or at negotiated prices. The difference between the price at which the underwriter purchases shares from us and the price at which the underwriter resells such shares may be deemed underwriting compensation. If the underwriter effects such
transactions by selling shares of common stock to or through dealers, such dealers may receive compensation in the form of discounts, concessions or commissions from the underwriter and/or purchasers of shares of common stock for whom they may act
as agents or to whom they may sell as principal. The expenses of the offering, not including the underwriting discounts and commissions, are estimated at $234,000 and are payable by us. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Option to Purchase Additional Shares </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We
have granted an option to the underwriter, exercisable for 30 days after the date of this prospectus supplement, to purchase up to 1,451,613 additional shares from us at a price of $14.75 per share. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>No Sales of Similar Securities </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We, our
executive officers and directors have agreed, subject to specified exceptions, not to directly or indirectly: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">sell, offer, contract or grant any option to sell (including any short sale), pledge, transfer, establish an open &#147;put equivalent position&#148; within the meaning of Rule 16a-l(h) under the Securities Exchange Act
of 1934, as amended (the &#147;Exchange Act&#148;), or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">otherwise dispose of any shares of common stock, options or warrants to acquire shares of common stock, or securities exchangeable or exercisable for or convertible into shares of common stock currently or hereafter
owned either of record or beneficially, or </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-12 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">publicly announce an intention to do any of the foregoing for a period of 90 days after the date of this prospectus supplement without the prior written consent of Cantor Fitzgerald&nbsp;&amp; Co. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This restriction terminates after the close of trading of the common stock on and including the 90th day after the date of this prospectus
supplement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cantor Fitzgerald&nbsp;&amp; Co. may, in its sole discretion and at any time or from time to time before the termination of
the 90-day period release all or any portion of the securities subject to lock-up agreements. Except for customary lock-up exceptions, including an exception allowing our directors and officers to make sales under preexisting 10b5-1 plans, there are
no existing agreements between the underwriter and any of our shareholders who will execute a lock-up agreement, providing consent to the sale of shares prior to the expiration of the lock-up period; provided however, that the lock-up agreement for
Kevin Tang, the Chairman of our Board of Directors, permits him to make gifts of securities subject to the lock-up agreement without requiring the recipient of such securities to execute a similar lock-up agreement. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>NASDAQ Capital Market Listing </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The shares
are listed on The NASDAQ Capital Market under the symbol &#147;HRTX.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Price Stabilization, Short Positions </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Until the distribution of the shares is completed, SEC rules may limit the underwriter from bidding for and purchasing our common stock.
However, the underwriter may engage in transactions that stabilize the price of the common stock, such as bids or purchases to peg, fix or maintain that price. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the offering, the underwriter may purchase and sell our common stock in the open market. These transactions may include
short sales, purchases on the open market to cover positions created by short sales and stabilizing transactions. Short sales involve the sale by the underwriter of a greater number of shares than it is required to purchase in the offering.
&#147;Covered&#148; short sales are sales made in an amount not greater than the underwriter&#146;s option to purchase additional shares described above. The underwriter may close out any covered short position by either exercising its option to
purchase additional shares or purchasing shares in the open market. In determining the source of shares to close out the covered short position, the underwriter will consider, among other things, the price of shares available for purchase in the
open market as compared to the price at which they may purchase shares through the option granted to them. &#147;Naked&#148; short sales are sales in excess of such option. The underwriter must close out any naked short position by purchasing shares
in the open market. A naked short position is more likely to be created if the underwriter is concerned that there may be downward pressure on the price of our common stock in the open market after pricing that could adversely affect investors who
purchase in the offering. Stabilizing transactions consist of various bids for or purchases of shares of common stock made by the underwriter in the open market prior to the completion of the offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Similar to other purchase transactions, the underwriter&#146;s purchases to cover the syndicate short sales may have the effect of raising or
maintaining the market price of our common stock or preventing or retarding a decline in the market price of our common stock. As a result, the price of our common stock may be higher than the price that might otherwise exist in the open market. The
underwriter may conduct these transactions on The NASDAQ Capital Market, in the over-the-counter market or otherwise. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Neither we nor the
underwriter make any representation or prediction as to the direction or magnitude of any effect that the transactions described above may have on the price of our common stock. In addition, neither we nor the underwriter make any representation
that it will engage in these transactions or that these transactions, once commenced, will not be discontinued without notice. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-13 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Passive Market Making </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The underwriter may also engage in passive market making transactions in our common stock on The NASDAQ Capital Market in accordance with Rule
103 of Regulation M under the Exchange Act during a period before the commencement of offers or sales of shares of our common stock in this offering and extending through the completion of distribution. A passive market maker must display its bid at
a price not in excess of the highest independent bid of that security. However, if all independent bids are lowered below the passive market maker&#146;s bid, that bid must then be lowered when specified purchase limits are exceeded. Passive market
making may cause the price of our common stock to be higher than the price that otherwise would exist in the open market in the absence of those transactions. The underwriter is not required to engage in passive market making and, if commenced, may
end passive market making activities at any time. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Electronic Distribution </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the offering, the underwriter may distribute this prospectus supplement and the accompanying prospectus by electronic means,
such as e-mail. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Other Relationships </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The underwriter and its affiliates have engaged in, and may in the future engage in, investment banking and other commercial dealings in the
ordinary course of business with us or our affiliates. They have received, or may in the future receive, customary fees and commissions for these transactions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, in the ordinary course of their business activities, the underwriter and its affiliates may make or hold a broad array of
investments and actively trade debt and equity securities (or related derivative securities) and financial instruments (including bank loans) for their own account and for the accounts of their customers. Such investments and securities activities
may involve securities and/or instruments of ours or our affiliates. The underwriter and its affiliates may also make investment recommendations and/or publish or express independent research views in respect of such securities or financial
instruments and may hold, or recommend to clients that they acquire, long and/or short positions in such securities and instruments. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Notice to
Prospective Investors in the European Economic Area </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In relation to each member state of the European Economic Area, no offer of shares
of common stock which are the subject of the offering has been, or will be made to the public in that Member State, other than under the following exemptions under the Prospectus Directive: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">A.</TD>
<TD ALIGN="left" VALIGN="top">to any legal entity which is a qualified investor as defined in the Prospectus Directive; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">B.</TD>
<TD ALIGN="left" VALIGN="top">to fewer than 100 or, if the Relevant Member State has implemented the relevant provision of the 2010 PD Amending Directive, 150, natural or legal persons (other than qualified investors as defined in the Prospectus
Directive), as permitted under the Prospectus Directive, subject to obtaining the prior consent of the underwriter; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">C.</TD>
<TD ALIGN="left" VALIGN="top">in any other circumstances falling within Article 3(2) of the Prospectus Directive, </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">provided that no such
offer of shares of common stock referred to in (a)&nbsp;to (c)&nbsp;above shall result in a requirement for the Company or the underwriter to publish a prospectus pursuant to Article 3 of the Prospectus Directive, or supplement a prospectus pursuant
to Article 16 of the Prospectus Directive. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each person located in a Member State to whom any offer of shares of common stock is made or
who receives any communication in respect of any offer of ordinary shares, or who initially acquires any shares of common stock will be deemed to have represented, warranted, acknowledged and agreed to and with the underwriter and the Company that
(1)&nbsp;it is a &#147;qualified investor&#148; within the meaning of the law in that Member </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-14 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
State implementing Article 2(1)(e) of the Prospectus Directive; and (2)&nbsp;in the case of any shares of common stock acquired by it as a financial intermediary as that term is used in Article
3(2) of the Prospectus Directive, the shares of common stock acquired by it in the offer have not been acquired on behalf of, nor have they been acquired with a view to their offer or resale to, persons in any Member State other than qualified
investors, as that term is defined in the Prospectus Directive, or in circumstances in which the prior consent of the underwriter has been given to the offer or resale; or where ordinary shares have been acquired by it on behalf of persons in any
Member State other than qualified investors, the offer of those ordinary shares to it is not treated under the Prospectus Directive as having been made to such persons. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company, the underwriter and their respective affiliates will rely upon the truth and accuracy of the foregoing representations,
acknowledgments and agreements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus supplement has been prepared on the basis that any offer of shares of common stock in any
Member State will be made pursuant to an exemption under the Prospectus Directive from the requirement to publish a prospectus for offers of shares of common stock. Accordingly, any person making or intending to make an offer in that Member State of
shares of common stock which are the subject of the offering contemplated in this prospectus supplement may only do so in circumstances in which no obligation arises for the Company or the underwriter to publish a prospectus pursuant to Article 3 of
the Prospectus Directive in relation to such offer. Neither the Company nor the underwriter have authorized, nor do they authorize, the making of any offer of shares of common stock in circumstances in which an obligation arises for the Company or
the underwriter to publish a prospectus for such offer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the purposes of this provision, the expression an &#147;offer of shares of
common stock to the public&#148; in relation to any shares of common stock in any Member State means the communication in any form and by any means of sufficient information on the terms of the offer and the shares of common stock to be offered so
as to enable an investor to decide to purchase or subscribe the shares of common stock, as the same may be varied in that Member State by any measure implementing the Prospectus Directive in that Member State, the expression &#147;Prospectus
Directive&#148; means Directive 2003/71/EC (as amended) and includes any relevant implementing measure in each Member State. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The above
selling restriction is in addition to any other selling restrictions set out below. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Notice to Prospective Investors in the United Kingdom </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, in the United Kingdom, this document is being distributed only to, and is directed only at, and any offer subsequently made may
only be directed at persons who are &#147;qualified investors&#148; (as defined in the Prospectus Directive) (i)&nbsp;who have professional experience in matters relating to investments falling within Article 19 (5)&nbsp;of the Financial Services
and Markets Act 2000 (Financial Promotion) Order 2005, as amended (Order), and/or (ii)&nbsp;who are high net worth companies (or persons to whom it may otherwise be lawfully communicated) falling within Article 49(2)(a) to (d)&nbsp;of the Order (all
such persons together being referred to as &#147;relevant persons&#148;). This document must not be acted on or relied on in the United Kingdom by persons who are not relevant persons. In the United Kingdom, any investment or investment activity to
which this document relates is only available to, and will be engaged in with, relevant persons. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Notice to Prospective Investors in Switzerland
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The shares may not be publicly offered in Switzerland and will not be listed on the SIX Swiss Exchange (SIX) or on any other stock
exchange or regulated trading facility in Switzerland. This document has been prepared without regard to the disclosure standards for issuance prospectuses under art. 652a or art. 1156 of the Swiss Code of Obligations or the disclosure standards for
listing prospectuses under art. 27 ff. of the SIX Listing Rules or the listing rules of any other stock exchange or regulated trading facility in Switzerland. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-15 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Neither this document nor any other offering or marketing material relating to the shares or
the offering may be publicly distributed or otherwise made publicly available in Switzerland. Neither this document nor any other offering or marketing material relating to the offering, us or the shares has been or will be filed with or approved by
any Swiss regulatory authority. In particular, this document will not be filed with, and the offer of shares will not be supervised by, the Swiss Financial Market Supervisory Authority FINMA, and the offer of shares has not been and will not be
authorized under the Swiss Federal Act on Collective Investment Schemes (CISA). The investor protection afforded to acquirers of interests in collective investment schemes under the CISA does not extend to acquirers of shares. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Notice to Prospective Investors in the Dubai International Financial Centre </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus supplement and the accompanying prospectus relate to an Exempt Offer in accordance with the Offered Securities Rules of the
Dubai Financial Services Authority (DFSA). This prospectus supplement and the accompanying prospectus are intended for distribution only to persons of a type specified in the Offered Securities Rules of the DFSA. They must not be delivered to, or
relied on by, any other person. The DFSA has no responsibility for reviewing or verifying any documents in connection with Exempt Offers. The DFSA has not approved this prospectus supplement and the accompanying prospectus nor taken steps to verify
the information set forth therein and has no responsibility for this prospectus supplement and the accompanying prospectus. The shares to which this prospectus supplement and the accompanying prospectus relate may be illiquid and/or subject to
restrictions on their resale. Prospective purchasers of the shares offered should conduct their own due diligence on the shares. If you do not understand the contents of this prospectus supplement and the accompanying prospectus you should consult
an authorized financial advisor. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Notice to Prospective Investors in Australia </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">No placement document, prospectus, product disclosure statement or other disclosure document has been lodged with the Australian Securities and
Investments Commission, in relation to the offering. This prospectus supplement and the accompanying prospectus do not constitute a prospectus, product disclosure statement or other disclosure document under the Corporations Act 2001 (Corporations
Act), and do not purport to include the information required for a prospectus, product disclosure statement or other disclosure document under the Corporations Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any offer in Australia of the shares may only be made to persons (Exempt Investors) who are &#147;sophisticated investors&#148; (within the
meaning of section 708(8) of the Corporations Act), &#147;professional investors&#148; (within the meaning of section 708(11) of the Corporations Act) or otherwise pursuant to one or more exemptions contained in section 708 of the Corporations Act
so that it is lawful to offer the shares without disclosure to investors under Chapter 6D of the Corporations Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The shares applied for
by Exempt Investors in Australia must not be offered for sale in Australia in the period of 12 months after the date of allotment under the offering, except in circumstances where disclosure to investors under Chapter 6D of the Corporations Act
would not be required pursuant to an exemption under section 708 of the Corporations Act or otherwise or where the offer is pursuant to a disclosure document which complies with Chapter 6D of the Corporations Act. Any person acquiring shares must
observe such Australian on-sale restrictions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus supplement and the accompanying prospectus contain general information only
and do not take account of the investment objectives, financial situation or particular needs of any particular person. They do not contain any securities recommendations or financial product advice. Before making an investment decision, investors
need to consider whether the information in this prospectus supplement and the accompanying prospectus is appropriate to their needs, objectives and circumstances, and, if necessary, seek expert advice on those matters. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-16 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Notice to Prospective Investors in Hong Kong </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The shares have not been offered or sold and will not be offered or sold in Hong Kong, by means of any document, other than (a)&nbsp;to
&#147;professional investors&#148; as defined in the Securities and Futures Ordinance (Cap. 571) of Hong Kong and any rules made under that Ordinance; or (b)&nbsp;in other circumstances which do not result in the document being a
&#147;prospectus&#148; as defined in the Companies Ordinance (Cap. 32) of Hong Kong or which do not constitute an offer to the public within the meaning of that Ordinance. No advertisement, invitation or document relating to the shares has been or
may be issued or has been or may be in the possession of any person for the purposes of issue, whether in Hong Kong or elsewhere, which is directed at, or the contents of which are likely to be accessed or read by, the public of Hong Kong (except if
permitted to do so under the securities laws of Hong Kong) other than with respect to shares which are or are intended to be disposed of only to persons outside Hong Kong or only to &#147;professional investors&#148; as defined in the Securities and
Futures Ordinance and any rules made under that Ordinance. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Notice to Prospective Investors in Japan </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The shares have not been and will not be registered under the Financial Instruments and Exchange Law of Japan (Law No.&nbsp;25 of 1948, as
amended) and, accordingly, will not be offered or sold, directly or indirectly, in Japan, or for the benefit of any Japanese Person or to others for re-offering or resale, directly or indirectly, in Japan or to any Japanese Person, except in
compliance with all applicable laws, regulations and ministerial guidelines promulgated by relevant Japanese governmental or regulatory authorities in effect at the relevant time. For the purposes of this paragraph, &#147;Japanese Person&#148; shall
mean any person resident in Japan, including any corporation or other entity organized under the laws of Japan. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Notice to Prospective Investors in
Singapore </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus supplement and the accompanying prospectus have not been registered as a prospectus with the Monetary
Authority of Singapore. Accordingly, this prospectus supplement and the accompanying prospectus and any other document or material in connection with the offer or sale, or invitation for subscription or purchase, of shares may not be circulated or
distributed, nor may the shares be offered or sold, or be made the subject of an invitation for subscription or purchase, whether directly or indirectly, to persons in Singapore other than (i)&nbsp;to an institutional investor under Section&nbsp;274
of the Securities and Futures Act, Chapter 289 of Singapore (SFA), (ii)&nbsp;to a relevant person pursuant to Section&nbsp;275(1), or any person pursuant to Section&nbsp;275(1A), and in accordance with the conditions specified in Section&nbsp;275,
of the SFA, or (iii)&nbsp;otherwise pursuant to, and in accordance with the conditions of, any other applicable provision of the SFA. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Where the shares are subscribed or purchased under Section&nbsp;275 of the SFA by a relevant person which is: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">a)</TD>
<TD ALIGN="left" VALIGN="top">a corporation (which is not an accredited investor (as defined in Section&nbsp;4A of the SFA)) the sole business of which is to hold investments and the entire share capital of which is owned by one or more individuals,
each of whom is an accredited investor; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">b)</TD>
<TD ALIGN="left" VALIGN="top">a trust (where the trustee is not an accredited investor) whose sole purpose is to hold investments and each beneficiary of the trust is an individual who is an accredited investor, </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">securities (as defined in Section&nbsp;239(1) of the SFA) of that corporation or the beneficiaries&#146; rights and interest (howsoever
described) in that trust shall not be transferred within six months after that corporation or that trust has acquired the shares pursuant to an offer made under Section&nbsp;275 of the SFA except: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">a)</TD>
<TD ALIGN="left" VALIGN="top">to an institutional investor or to a relevant person defined in Section&nbsp;275(2) of the SFA, or to any person arising from an offer referred to in Section&nbsp;275(1A) or Section&nbsp;276(4)(i)(B) of the SFA;
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">b)</TD>
<TD ALIGN="left" VALIGN="top">where no consideration is or will be given for the transfer; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">c)</TD>
<TD ALIGN="left" VALIGN="top">where the transfer is by operation of law; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-17 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">d)</TD>
<TD ALIGN="left" VALIGN="top">as specified in Section&nbsp;276(7) of the SFA; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">e)</TD>
<TD ALIGN="left" VALIGN="top">as specified in Regulation 32 of the Securities and Futures (Offers of Investments) (Shares and Debentures) Regulations 2005 of Singapore. </TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Notice to Prospective Investors in Canada </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus supplement constitutes an &#147;exempt offering document&#148; as defined in and for the purposes of applicable Canadian
securities laws. No prospectus has been filed with any securities commission or similar regulatory authority in Canada in connection with the offer and sale of the common stock. No securities commission or similar regulatory authority in Canada has
reviewed or in any way passed upon this prospectus supplement or on the merits of the common stock and any representation to the contrary is an offence. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Canadian investors are advised that this prospectus supplement has been prepared in reliance on section 3A.3 of National Instrument 33-105
Underwriting Conflicts (&#147;NI 33-105&#148;). Pursuant to section 3A.3 of NI 33-105, this prospectus supplement is exempt from the requirement that the Company and the underwriter provide investors with certain conflicts of interest disclosure
pertaining to &#147;connected issuer&#148; and/or &#147;related issuer&#148; relationships that may exist between the Company and the underwriter as would otherwise be required pursuant to subsection 2.1(1) of NI 33-105. </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Resale Restrictions </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The offer and sale of the common stock in Canada is being made on a private placement basis only and is exempt from the requirement that the
Company prepares and files a prospectus under applicable Canadian securities laws. Any resale of the common stock acquired by a Canadian investor in this offering must be made in accordance with applicable Canadian securities laws, which may vary
depending on the relevant jurisdiction, and which may require resales to be made in accordance with Canadian prospectus requirements, pursuant to a statutory exemption from the prospectus requirements, in a transaction exempt from the prospectus
requirements or otherwise under a discretionary exemption from the prospectus requirements granted by the applicable local Canadian securities regulatory authority. These resale restrictions may under certain circumstances apply to resales of the
common stock outside of Canada. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Representations of Purchasers </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each Canadian investor who purchases the common stock will be deemed to have represented to the Company and the underwriter(s) that the
investor (i)&nbsp;is purchasing the common stock as principal, or is deemed to be purchasing as principal in accordance with applicable Canadian securities laws, for investment only and not with a view to resale or redistribution; (ii)&nbsp;is an
&#147;accredited investor&#148; as such term is defined in section 1.1 of National Instrument 45-106 <I>Prospectus Exemptions</I> (&#147;NI 45-106&#148;) or, in Ontario, as such term is defined in section 73.3(1) of the <I>Securities Act</I>
(Ontario); and (iii)&nbsp;is a &#147;permitted client&#148; as such term is defined in section 1.1 of National Instrument 31-103 <I>Registration Requirements, Exemptions and Ongoing Registrant Obligations</I>. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Taxation and Eligibility for Investment </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any discussion of taxation and related matters contained in this prospectus supplement does not purport to be a comprehensive description of
all of the tax considerations that may be relevant to a Canadian investor when deciding to purchase the common stock and, in particular, does not address any Canadian tax considerations. No representation or warranty is hereby made as to the tax
consequences to a resident, or deemed resident, of Canada of an investment in the common stock or with respect to the eligibility of the common stock for investment by such investor under relevant Canadian federal and provincial legislation and
regulations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Rights of Action for Damages or Rescission </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Securities legislation in certain of the Canadian jurisdictions provides certain purchasers of securities pursuant to an offering memorandum
(such as this prospectus supplement), including where the distribution </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-18 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
involves an &#147;eligible foreign security&#148; as such term is defined in Ontario Securities Commission Rule 45-501 <I>Ontario Prospectus and Registration Exemptions</I> and in Multilateral
Instrument 45-107 <I>Listing Representation and Statutory Rights of Action Disclosure Exemptions</I>, as applicable, with a remedy for damages or rescission, or both, in addition to any other rights they may have at law, where the offering
memorandum, or other offering document that constitutes an offering memorandum, and any amendment thereto, contains a &#147;misrepresentation&#148; as defined under applicable Canadian securities laws. These remedies, or notice with respect to these
remedies, must be exercised or delivered, as the case may be, by the purchaser within the time limits prescribed under, and are subject to limitations and defences under, applicable Canadian securities legislation. In addition, these remedies are in
addition to and without derogation from any other right or remedy available at law to the investor. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Language of Documents
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon receipt of this document, each Canadian investor hereby confirms that it has expressly requested that all documents
evidencing or relating in any way to the sale of the securities described herein (including for greater certainty any purchase confirmation or any notice) be drawn up in the English language only. <I>Par la r&eacute;ception de ce document, chaque
investisseur Canadien confirme par les pr&eacute;sentes qu&#146;il a express&eacute;ment exig&eacute; que tous les documents faisant foi ou se rapportant de quelque mani&egrave;re que ce soit &agrave; la vente des valeurs mobili&egrave;res
d&eacute;crites aux pr&eacute;sentes (incluant, pour plus de certitude, toute confirmation d&#146;achat ou tout avis) soient r&eacute;dig&eacute;s en anglais seulement.</I> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-19 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supptoc504779_21"></A>LEGAL MATTERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Gibson, Dunn&nbsp;&amp; Crutcher LLP of San Francisco, California will pass upon the validity of the shares of common stock offered hereby.
Latham&nbsp;&amp; Watkins LLP of San Diego, California is counsel to the underwriter in connection with this offering. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-20 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supptoc504779_22"></A>EXPERTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">OUM&nbsp;&amp; Co. LLP, an independent registered public accounting firm, has audited our consolidated financial statements included in our
Annual Report on Form 10-K for the year ended December&nbsp;31, 2016, as set forth in their report, which is incorporated by reference in this prospectus supplement and elsewhere in the registration statement. Our consolidated financial statements
are incorporated by reference in reliance on OUM&nbsp;&amp; Co. LLP&#146;s report, given on their authority as experts in accounting and auditing. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-21 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supptoc504779_23"></A>INFORMATION INCORPORATED BY REFERENCE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The SEC allows the Company to &#147;incorporate by reference&#148; the information that is filed by the Company with the SEC, which means that
the Company can disclose important information to you by referring you to those documents. The documents incorporated by reference are: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top">The Company&#146;s Annual Report on Form 10-K for the fiscal year ended December&nbsp;31, 2016; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top">Portions of our Definitive Proxy Statement on Schedule 14A filed with the SEC on April&nbsp;26, 2017 that have been incorporated by reference into our Annual Report on Form 10-K for the year ended December&nbsp;31,
2016; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top">The Company&#146;s Quarterly Reports on Form 10-Q for the quarters ended March&nbsp;31, 2017,&nbsp;June&nbsp;30, 2017 and September&nbsp;30, 2017; </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top">The Company&#146;s Current Reports on Form 8-K filed with the SEC on January&nbsp;24, 2017,&nbsp;March&nbsp;17, 2017,&nbsp;April&nbsp;3, 2017, April&nbsp;24, 2017,&nbsp;June&nbsp;13, 2017, October&nbsp;26, 2017 and
November&nbsp;9, 2017; and </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">5.</TD>
<TD ALIGN="left" VALIGN="top">The description of the Company&#146;s common stock contained in Amendment No.&nbsp;3 to that certain registration statement on Form&nbsp;8-A, filed with the SEC on July&nbsp;6, 2017 pursuant to Section&nbsp;12 of the
Exchange Act, including any amendment or report filed for the purpose of updating that description. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All documents we file
with the SEC pursuant to Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act, except as to any portion of any report or documents that is not deemed filed under such provisions, on or after the date of this prospectus supplement until the earlier
of the date on which all of the securities registered hereunder have been sold or the registration statement of which this prospectus supplement is a part has been withdrawn, shall be deemed incorporated by reference in this prospectus supplement
and to be a part of this prospectus supplement from the date of filing of those documents. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any statement contained in a document
incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded, for purposes of this prospectus supplement, to the extent that a statement contained in or omitted from this prospectus supplement, or in any
other subsequently filed document that also is or is deemed to be incorporated by reference herein, modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to
constitute a part of this prospectus supplement. Nothing in this prospectus supplement shall be deemed to incorporate information furnished but not filed with the SEC pursuant to Item&nbsp;2.02 or Item&nbsp;7.01 of Form 8-K. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon written or oral request, we will provide, without charge, to each person, including any beneficial owner, to whom a copy of this
prospectus supplement is delivered, upon such person&#146;s written or oral request, a copy of any and all of the information incorporated by reference in this prospectus supplement, other than exhibits to such documents, unless such exhibits are
specifically incorporated by reference into the information that this prospectus supplement incorporates. Requests should be directed to the Secretary at Heron Therapeutics, Inc., 4242 Campus Point Court, Suite 200, San Diego, California 92121,
telephone number (858)&nbsp;251-4400. You may also find these documents in the &#147;Investor Relations&#148; section of our website,<I> www.herontx.com</I>. The information on our website is not incorporated into this prospectus supplement. We have
authorized no one to provide you with any information that differs from that contained in this prospectus supplement. Accordingly, you should not rely on any information that is not contained in this prospectus supplement. You should not assume that
the information in this prospectus is accurate as of any date other than the date of the front cover of this prospectus supplement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-22 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supptoc504779_24"></A>WHERE YOU CAN FIND ADDITIONAL INFORMATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company is subject to the informational requirements of the Exchange Act, and in accordance therewith, files annual, quarterly and special
reports, proxy statements and other information with the SEC. You may read and copy any document filed by the Company at the SEC&#146;s Public Reference Room at 100 F Street, N.E., Washington, D.C. 20549. Please call the SEC at 1-800-SEC-0330 for
further information on the public reference room. The Company&#146;s filings with the SEC are also available to the public at the SEC&#146;s Internet web site at<I> http://www.sec.gov</I>. Statements contained in this prospectus supplement as to the
contents of any contract or other document are not necessarily complete, and in each instance we refer you to the copy of the contract or document filed as an exhibit to the registration statement, each such statement being qualified in all respects
by such reference. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-23 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>PROSPECTUS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g504779g04j69.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Common Stock </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Preferred Stock </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Warrants
</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under this prospectus, we or any selling stockholder may offer and sell from time to time, in one or more offerings, an indeterminate number
of shares of our common stock, preferred stock, and warrants or any combination thereof, separately, together or in series. The warrants may be convertible into or exercisable or exchangeable for common stock or preferred stock and the preferred
stock may be convertible into or exchangeable for common stock. Each time securities are offered or sold pursuant to this prospectus, we will describe in a prospectus supplement the securities being offered and sold, as well as the specific terms of
the securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our common stock is listed on The NASDAQ Capital Market under the symbol &#147;HRTX.&#148; On July&nbsp;5, 2017, the last
reported sale price on The NASDAQ Capital Market was $14.00 per share. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You should read this prospectus, any prospectus supplement and the
documents incorporated by reference in this prospectus and any prospectus supplement carefully before you invest. This prospectus may not be used to offer or sell any of our common stock, preferred stock or warrants unless accompanied by a
prospectus supplement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We or any selling stockholder may offer these securities in amounts, at prices and on terms determined at the time
of offering. We or any selling stockholder may sell the securities directly to investors, through agents we select, or through underwriters and dealers we select. See &#147;Plan of Distribution&#148; in this prospectus. Each prospectus supplement
will provide the amount, price, terms and plan of distribution relating to the securities to be sold pursuant to such prospectus supplement. If agents, underwriters or dealers are used to sell the securities, we will name them and describe their
compensation in a prospectus supplement or sales agreement prospectus. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:12pt; font-family:Times New Roman"><B>Investing in
our securities involves certain risks. See &#147;<A HREF="#toc504779_4">Risk Factors</A>&#148; beginning on Page&nbsp;5 of this prospectus and in the applicable prospectus supplement and any related free writing prospectus, and in the other
documents that are incorporated by reference into this prospectus or the applicable prospectus supplement, for certain risks you should consider. You should read the entire prospectus carefully before you make your investment decision. </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or
determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense. </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>The date of
this prospectus is July&nbsp;6, 2017 </B></P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc"></A>TABLE OF CONTENTS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="95%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">Page</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc504779_1">ABOUT THIS PROSPECTUS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc504779_2">NOTE REGARDING FORWARD-LOOKING STATEMENTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc504779_3">ABOUT THE COMPANY</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc504779_4">RISK FACTORS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc504779_5">USE OF PROCEEDS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc504779_6">RATIO OF EARNINGS TO FIXED CHARGES</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc504779_7">DESCRIPTION OF SECURITIES</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc504779_8">SELLING STOCKHOLDERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc504779_9">PLAN OF DISTRIBUTION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc504779_10">EXPERTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc504779_11">LEGAL MATTERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc504779_12">INFORMATION INCORPORATED BY REFERENCE</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc504779_13">WHERE YOU CAN FIND ADDITIONAL INFORMATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You should rely only on the information contained or incorporated by reference into this prospectus and any
prospectus supplement or any free writing prospectus that we may provide to you. We have not authorized anyone to provide you with different information. You must not rely upon any unauthorized information or representation. You should not assume
that the information contained in this prospectus or any applicable prospectus supplement is accurate as of any date other than the date on the front cover of the prospectus or the prospectus supplement or that the information contained in any
document incorporated by reference is accurate as of any date other than the date of the document incorporated by reference. Our business, financial condition, results of operations and prospects may have changed since those dates. We are not making
offers to sell the securities in any jurisdiction in which an offer or solicitation is not authorized or permitted or in which the person making such offer or solicitation is not qualified to do so or to anyone to whom it is unlawful to make an
offer or solicitation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Heron Therapeutics<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>, the Heron logo, SUSTOL<SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP>, CINVANTI&#153; and Biochronomer<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> are our trademarks. All other trademarks appearing or incorporated by reference into this prospectus and
any applicable prospectus supplement are the property of their respective owners. </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc504779_1"></A>ABOUT THIS PROSPECTUS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus is part of an automatic shelf registration statement that we filed with the Securities and Exchange Commission, or the SEC, as
a &#147;well-known seasoned issuer&#148; as defined in Rule&nbsp;405 under the Securities Act of 1933, as amended, or the Securities Act. Under this shelf registration statement, we and/or selling stockholders may offer shares of our common stock
and preferred stock, various series of warrants to purchase common stock or preferred stock, or any combination thereof, from time to time in one or more offerings under this prospectus at prices and on terms to be determined by market conditions at
the time of offering. This prospectus only provides you with a general description of the securities we and/or selling stockholders may offer. Each time we and/or selling stockholders offer a type or series of securities under this prospectus, we
will provide a prospectus supplement to this prospectus that will contain more specific information about the securities being offered and specific terms of the offering. We may also authorize one or more free writing prospectuses to be provided to
you that may contain material information relating to these offerings. This prospectus may not be used to sell our securities unless accompanied by a prospectus supplement. Each such prospectus supplement and any related free writing prospectus that
we may authorize to be provided to you may also add, update or change information contained in this prospectus or in documents incorporated by reference into this prospectus. If there is any inconsistency between the information in this prospectus
and the applicable prospectus supplement or related free writing prospectus, you should rely on the prospectus supplement or any related free writing prospectus we may authorize to be provided to you. We urge you to carefully read this prospectus,
any applicable prospectus supplement and any related free writing prospectus, together with the information incorporated herein by reference as described under the headings &#147;Information Incorporated by Reference&#148; and &#147;Where You Can
Find Additional Information&#148; before you invest in our securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Neither we nor any selling stockholder have authorized anyone to
provide you with information in addition to or different from that contained in this prospectus, any applicable prospectus supplement and any related free writing prospectus. We take no responsibility for, and can provide no assurances as to the
reliability of, any information not contained in this prospectus, any applicable prospectus supplement or any related free writing prospectus that we may authorize to be provided to you. This prospectus is an offer to sell only the securities
offered hereby, but only under circumstances and in jurisdictions where it is lawful to do so. You should assume that the information in this prospectus, any applicable prospectus supplement or any related free writing prospectus is accurate only as
of the date on the front of the document (unless the information specifically indicates that another date applies) and that any information incorporated by reference is accurate only as of the date of the document incorporated by reference,
regardless of the time of delivery of this prospectus, any applicable prospectus supplement or any related free writing prospectus, or any sale of a security. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus contains summaries of certain provisions contained in some of the documents described herein, but reference is made to the
actual documents for complete information. All of the summaries are qualified in their entirety by the actual documents. Copies of some of the documents referred to herein have been filed, will be filed or will be incorporated by reference as
exhibits to the registration statement of which this prospectus is a part, and you may obtain copies of those documents as described below under the heading &#147;Where You Can Find Additional Information.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc504779_2"></A>NOTE REGARDING FORWARD-LOOKING STATEMENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus contains forward-looking statements within the meaning of the federal securities laws. We make such forward-looking statements
pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. You can identify forward-looking statements by the use of the words &#147;believe,&#148; &#147;expect,&#148;
&#147;anticipate,&#148; &#147;intend,&#148; &#147;estimate,&#148; &#147;project,&#148; &#147;will,&#148; &#147;should,&#148; &#147;may,&#148; &#147;plan,&#148; &#147;assume&#148; and other expressions that predict or indicate future events and
trends and which do not relate to historical matters. You should not rely on forward-looking statements, because they involve known and unknown risks, uncertainties and other factors, some of which are beyond our control. These risks, uncertainties
and other factors may cause our actual results, performance or achievements to be materially different from the anticipated future results, performance or achievements expressed or implied by the forward-looking statements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Factors that might cause these differences include the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our ability to successfully commercialize, market and achieve market acceptance of SUSTOL<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> (granisetron) extended-release injection (&#147;SUSTOL&#148;) and for
future product candidates, including our positioning relative to competing products; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">estimates of the outcomes of our New Drug Application (&#147;NDA&#148;) submission to the U.S. Food and Drug Administration (&#147;FDA&#148;) for CINVANTI&#153; (HTX-019) (&#147;CINVANTI&#148;) and potential regulatory
approval for and commercial launch of CINVANTI; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any limitations or unfavorable warning or cautionary language that the FDA may ultimately impose on the label for CINVANTI; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the potential market opportunities for SUSTOL, CINVANTI and HTX-011; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our competitors&#146; activities, including decisions as to the timing of competing product launches, generic entrants, pricing and discounting; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">whether safety and efficacy results of our clinical trials and other required tests for approval of our product candidates provide data to warrant progression of clinical trials, potential regulatory approval or further
development of any of our product candidates; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our ability to meet the post-marketing study requirements within the FDA&#146;s mandated timelines and to obtain favorable results and comply with standard post-marketing requirements including U.S. federal advertising
and promotion laws, federal and state anti-fraud and abuse laws, healthcare information privacy and security laws, safety surveillance, and disclosure of payments or other transfers of value to healthcare professionals and entities for SUSTOL or any
of our product candidates; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our ability to successfully develop and achieve regulatory approval for other future product candidates utilizing our proprietary Biochronomer<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> sustained-release
drug delivery technology; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our ability to establish key collaborations and vendor relationships for our products and any other future product candidates; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our ability to successfully develop and commercialize any technology that we may in-license or products we may acquire; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">unanticipated delays due to manufacturing difficulties, supply constraints or changes in the regulatory environment; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our ability to successfully operate in non-U.S. jurisdictions in which we may choose to do business, including compliance with applicable regulatory requirements and laws; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">uncertainties associated with obtaining and enforcing patents to protect our products, and our ability to successfully defend ourselves against unforeseen third-party infringement claims; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our estimates regarding our capital requirements; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our ability to obtain additional financing and raise capital as necessary to fund operations or pursue business opportunities. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any forward-looking statements in this prospectus reflect our current views with respect to future events or to our future financial
performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by
these forward-looking statements. Factors that may cause actual results to differ materially from current expectations include, among other things, those listed under the section entitled &#147;Risk Factors&#148; in this prospectus, as may be
updated from time to time by our future filings under the Securities Exchange Act of 1934, as amended, or the Exchange Act, and discussed elsewhere in this prospectus and the documents incorporated by reference herein. You should carefully review
all of these factors. Given these uncertainties, you should not place undue reliance on these forward-looking statements. These forward-looking statements were based on information, plans and estimates as of the date of this prospectus, and except
as required by law, we assume no obligation to update any forward-looking statements to reflect changes in underlying assumptions or factors, new information, future events or other changes. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus may also contain estimates, projections and other information concerning our industry, our business, and the markets for
certain diseases, including data regarding the estimated size of those markets. Information that is based on estimates, forecasts, projections, market research or similar methodologies is inherently subject to uncertainties and actual events or
circumstances may differ materially from events and circumstances reflected in this information. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc504779_3"></A>ABOUT THE COMPANY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Unless the context requires otherwise, in this Prospectus, the &#147;Company,&#148; &#147;Heron&#148; &#147;we,&#148; &#147;us&#148; and
&#147;our&#148; refer to Heron Therapeutics, Inc. </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Heron Therapeutics, Inc. is a commercial-stage biotechnology company focused on
improving the lives of patients by developing novel best-in-class treatments that address some of the biggest unmet patient needs. Heron is developing novel, patient-focused solutions that apply its innovative science and technologies to
already-approved pharmacological agents for patients suffering from cancer or pain. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our common stock is listed on The NASDAQ Capital
Market under the symbol &#147;HRTX.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We were founded in February 1983 as a California corporation under the name AMCO Polymerics,
Inc., or AMCO. AMCO changed its name to Advanced Polymer Systems, Inc. in 1984 and was reincorporated in the state of Delaware in 1987. We changed our name to A.P. Pharma, Inc. in May 2001 and changed our name from A.P. Pharma, Inc. to Heron
Therapeutics, Inc. in January 2014. Our executive offices are located at 4242 Campus Point Court, Suite 200, San Diego, California 92121 and our telephone number is (858)&nbsp;251-4400. Additional information regarding our company, including our
audited financial statements and descriptions of our business, is contained in the documents incorporated by reference in this prospectus. See &#147;Where You Can Find Additional Information&#148; on page&nbsp;13 and &#147;Information Incorporated
by Reference&#148; beginning on page&nbsp;13. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc504779_4"></A>RISK FACTORS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Investing in our securities involves a high degree of risk. Before you decide whether to purchase any of our securities, in addition to the
other information, documents or reports included in or incorporated by reference into this prospectus and any accompanying prospectus supplement or other offering materials, you should carefully consider the risk factors in the section entitled
&#147;Risk Factors&#148; in any prospectus supplement to this prospectus as well as in our most recent Annual Report on Form&nbsp;10-K and any subsequent Quarterly Reports on Form&nbsp;10-Q, which are incorporated by reference into this prospectus
and any prospectus supplement in their entirety, as the same may be amended, supplemented or superseded from time to time by our filings under the Exchange Act. For additional information, see the section entitled &#147;Where You Can Find Additional
Information.&#148; These risks could materially and adversely affect our business, results of operations, financial condition and prospects and could result in a partial or complete loss of your investment. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc504779_5"></A>USE OF PROCEEDS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We intend to use the net proceeds we receive from the sale of securities as set forth in the applicable prospectus supplement. Unless
otherwise set forth in a prospectus supplement, we will not receive any proceeds from the sale of securities by any selling stockholder. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc504779_6"></A>RATIO OF EARNINGS TO FIXED CHARGES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we offer preference equity securities under this prospectus, then we will, if required at that time, provide a ratio of combined fixed
charges and preference dividends to earnings in the applicable prospectus supplement for such offering or in a document that we file with the SEC and incorporate by reference in the future. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc504779_7"></A>DESCRIPTION OF SECURITIES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Description of Capital Stock </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following is a description of our common stock and a summary of our preferred stock. You should refer to our certificate of incorporation
and our bylaws for the actual terms of our capital stock. Copies of our certificate of incorporation and bylaws may be obtained as described under the heading &#147;Where You Can Find Additional Information&#148; in this prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are authorized to issue up to 102,500,000 shares of capital stock of which 100,000,000 shares are of common stock, par value $0.01 per
share, and 2,500,000 shares are of preferred stock, par value $0.01 per share. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Common Stock </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The holders of common stock are entitled to one vote per share on all matters to be voted upon by the stockholders. Subject to preferences that
may be applicable to any outstanding preferred stock, the holders of common stock are entitled to receive ratably all dividends, if any, as may be declared form time to time by our Board of Directors out of the funds legally available. In the event
of the liquidation, dissolution or winding up of the Company, the holders of our common stock are entitled to share ratably in all assets remaining after payment of liabilities, subject to prior distribution rights of preferred stock, if any, then
outstanding. The common stock has no preemptive or conversion rights. There are no redemption or sinking fund provisions applicable to the common stock. All outstanding shares of common stock are fully paid and non-assessable, and the shares of
common stock to be issued upon completion of this offering will be fully paid and non-assessable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of April&nbsp;17, 2017,
53,696,906&nbsp;shares of our common stock were issued and outstanding. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Transfer Agent and Registrar. </I>The transfer agent and
registrar for our common stock is Computershare Trust Company&nbsp;N.A. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Listing. </I>Our common stock is currently listed on The
NASDAQ Capital Market under the symbol &#147;HRTX.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Preferred Stock </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under our certificate of incorporation, our Board of Directors has the authority, without further action by stockholders, to designate up to
2,500,000 shares of preferred stock in one or more series and to fix the rights, preferences, privileges, qualifications and restrictions granted to or imposed upon the preferred stock, including dividend rights, conversion rights, voting rights,
rights and terms of redemption, liquidation preference and sinking fund terms, any or all of which may be greater than the rights of the common stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of April&nbsp;17, 2017, no shares of preferred stock were issued and outstanding. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we issue preferred stock, we will fix the rights, preferences, privileges, qualifications and restrictions of the preferred stock of each
series that we sell under this prospectus and applicable prospectus supplements in the certificate of designations relating to that series. If we issue preferred stock, we will incorporate by reference into the registration statement of which this
prospectus is a part the form of any certificate of designations that describes the terms of the series of preferred stock we are offering before the issuance of the related series of preferred stock. We urge you to read the prospectus supplement
and any free writing prospectus related to any series of preferred stock we may offer, as well as the complete certificate of designations that contains the terms of the applicable series of preferred stock. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Certain Provisions Affecting Control of Heron Therapeutics </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Certificate of Incorporation and Bylaw Provisions</I>. Some provisions of Delaware law and our certificate of incorporation and bylaws
contain provisions that could make the following transactions more difficult: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">acquisition of us by means of a tender offer; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">acquisition of us by means of a proxy contest or otherwise; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">removal of our incumbent officers and directors. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These provisions, summarized below, are
intended to discourage coercive takeover practices and inadequate takeover bids and to promote stability in our management. These provisions are also designed to encourage persons seeking to acquire control of us to first negotiate with our Board of
Directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Undesignated Preferred Stock</I>. The ability to authorize undesignated preferred stock makes it possible for our Board of
Directors to issue one or more series of preferred stock with voting or other rights or preferences that could impede the success of any attempt to change control of us. These and other provisions may have the effect of deferring hostile takeovers
or delaying changes in control or management of our company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Advance Notice Procedures</I>. The advance notice procedures in our
bylaws with regard to stockholder proposals relating to the nomination of candidates for election as directors or new business to be brought before meetings of our stockholders provide that notice of stockholder proposals must be timely given in
writing to our corporate secretary prior to the meeting at which the action is to be taken. Generally, to be timely, notice must be received at our principal executive offices not less than 90 days nor more than 120 days prior to the first
anniversary date of the annual meeting for the preceding year. Our bylaws specify the requirements as to form and content of all such stockholder notices. These requirements may have the effect of precluding stockholders from bringing proposals
relating to the nomination of candidates for election as directors or new business before the stockholders at an annual or special meeting. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Delaware Anti-Takeover Statute</I>. We are subject to Section&nbsp;203 of the General Corporation Law of the State of Delaware. This law
prohibits a publicly held Delaware corporation from engaging in any business combination with any interested stockholder for a period of three years following the date that the stockholder became an interested stockholder unless: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">prior to the date of the transaction, the board of directors of the corporation approved either the business combination or the transaction which resulted in the stockholder becoming an interested stockholder;
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">upon consummation of the transaction that resulted in the stockholder becoming an interested stockholder, the interested stockholder owned at least 85% of the voting stock of the corporation outstanding at the time the
transaction commenced, excluding for purposes of determining the number of shares outstanding those shares owned by persons who are directors and also officers and by employee stock plans in which employee participants do not have the right to
determine confidentially whether shares held subject to the plan will be tendered in a tender or exchange offer; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">on or subsequent to the date of the transaction, the business combination is approved by the board of directors and authorized at an annual or special meeting of stockholders, and not by written consent, by the
affirmative vote of at least two-thirds of the outstanding voting stock which is not owned by the interested stockholder. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Section&nbsp;203
defines &#147;business combination&#148; to include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any merger or consolidation involving the corporation and the interested stockholder; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any sale, transfer, pledge or other disposition of 10% or more of our assets involving the interested stockholder; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">in general, any transaction that results in the issuance or transfer by us of any of our stock to the interested stockholder; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the receipt by the interested stockholder of the benefit of any loans, advances, guarantees, pledges or other financial benefits provided by or through the corporation. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In general, Section&nbsp;203 defines an &#147;interested stockholder&#148; as an entity or person beneficially owning 15% or more of the
outstanding voting stock of the corporation and any entity or person affiliated with or controlling or controlled by the entity or person. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Description of Warrants </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>General
Description of Warrants </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may issue warrants for the purchase of common stock, preferred stock or any combination of these
securities. Warrants may be issued independently or together with other securities and may be attached to or separate from any offered securities. Each series of warrants will be issued under a separate warrant agreement to be entered into between a
warrant agent and us. The warrant agent will act solely as our agent in connection with the warrants and will not have any obligation or relationship of agency or trust for or with any holders or beneficial owners of warrants. The following outlines
some of the general terms and provisions of the warrants that we may issue from time to time. Additional terms of the warrants and the applicable warrant agreement will be set forth in the applicable prospectus supplement. The following description,
and any description of the warrants included in a prospectus supplement, may not be complete and is subject to and qualified in its entirety by reference to the terms and provisions of the applicable warrant agreement, which we will file with the
SEC in connection with any offering of warrants. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Stock Warrants </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The prospectus supplement relating to a particular issue of warrants exercisable for common stock or preferred stock will describe the terms of
the common stock warrants and preferred stock warrants, including the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the title of the warrants; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the offering price for the warrants, if any; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the aggregate number of the warrants; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the designation and terms of the common stock or preferred stock that may be purchased upon exercise of the warrants; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">if applicable, the designation and terms of the securities that the warrants are issued with and the number of warrants issued with each security; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">if applicable, the date from and after which the warrants and any securities issued with the warrants will be separately transferable; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the number of shares and price of common stock or preferred stock that may be purchased upon exercise of a warrant; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the dates on which the right to exercise the warrants commences and expires; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">if applicable, the minimum or maximum amount of the warrants that may be exercised at any one time; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">if applicable, a discussion of material U.S. federal income tax considerations; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">anti-dilution provisions of the warrants, if any; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">redemption or call provisions, if any, applicable to the warrants; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any additional terms of the warrants, including terms, procedures and limitations relating to the exchange and exercise of the warrants. </TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Exercise of Warrants </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each warrant
will entitle the holder of the warrant to purchase at the exercise price set forth in the applicable prospectus supplement the number of shares of common stock or preferred stock being offered. Holders may exercise warrants at any time up to the
close of business on the expiration date set forth in the applicable prospectus supplement. After the close of business on the expiration date, unexercised warrants will be void. Holders may exercise warrants as set forth in the prospectus
supplement relating to the warrants being offered. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Until a holder exercises the warrants to purchase any securities underlying the
warrants, the holder will not have any rights as a holder of the underlying securities by virtue of ownership of warrants. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>S<A NAME="toc504779_8"></A>ELLING STOCKHOLDERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Selling stockholders are persons or entities that, directly or indirectly, have acquired or will from time to time acquire from us, our
securities. Such selling stockholders may be parties to registration rights agreements with us, or we otherwise may have agreed or will agree to register their securities for resale. The initial purchasers of our securities, as well as their
transferees, pledgees, donees or successors, all of whom we refer to as &#147;selling stockholders,&#148; may from time to time offer and sell our securities pursuant to this prospectus, any applicable prospectus supplement or post-effective
amendment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Information regarding the beneficial ownership of our securities by a selling stockholder, the number of securities being
offered by a selling stockholder and the number of securities beneficially owned by a selling stockholder after the applicable offering, where applicable, will be set forth in a prospectus supplement or in a post-effective amendment. The applicable
prospectus supplement or post-effective amendment will also disclose whether any of the selling stockholders has held any position or office with, has been employed by or otherwise has had a material relationship with us during the three years prior
to the date of the applicable prospectus supplement or post-effective amendment. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc504779_9"></A>PLAN OF DISTRIBUTION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may sell the securities covered by this prospectus from time to time in one or more offerings. Registration of the securities covered by
this prospectus does not mean, however, that those securities will necessarily be offered or sold. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may sell the securities separately
or together: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">through one or more underwriters or dealers in a public offering and sale by them; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">directly to investors; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">through agents. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may sell the securities from time to time: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">in one or more transactions at a fixed price or prices, which may be changed from time to time; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">at market prices prevailing at the times of sale; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">at prices related to such prevailing market prices; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">at negotiated prices. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will describe the method of distribution of the securities issued
pursuant to this prospectus and the terms of the offering in the applicable prospectus supplement. Discounts or concessions allowed or re-allowed or paid to dealers may be changed from time to time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If underwriters are used in the sale of any securities, the securities will be acquired by the underwriters for their own account and may be
resold from time to time in one or more transactions described above. The securities may be either offered to the public through underwriting syndicates represented by managing underwriters, or directly by underwriters. Generally, the
underwriters&#146; obligations to purchase the securities will be subject to conditions precedent and the underwriters will be obligated to purchase all of the securities if they purchase any of the securities. We may use underwriters with whom we
have a material relationship. We will describe in the applicable prospectus supplement, naming the underwriter, the nature of any such relationship. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may authorize underwriters, dealers or agents to solicit offers by certain purchasers to purchase the securities from us at the public
offering price set forth in the applicable prospectus supplement pursuant to delayed delivery contracts providing for payment and delivery on a specified date in the future. The contracts will be subject only to those conditions set forth in the
applicable prospectus supplement, and the applicable prospectus supplement will set forth any commissions we pay for solicitation of these contracts. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Underwriters, dealers and agents may be entitled to indemnification by us against certain civil liabilities, including liabilities under the
Securities Act, or to contribution with respect to payments made by the underwriters, dealers or agents, under agreements between us and the underwriters, dealers and agents. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may grant underwriters who participate in the distribution of securities an option to purchase additional securities to cover
over-allotments, if any, in connection with the distribution. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Underwriters, dealers or agents may receive compensation in the form of
discounts, concessions or commissions from us or our purchasers, as their agents in connection with the sale of securities. These underwriters, dealers or agents may be considered to be underwriters under the Securities Act. As a result, discounts,
commissions or profits on resale received by the underwriters, dealers or agents may be treated as underwriting discounts and commissions. The applicable prospectus supplement will identify any such underwriter, dealer or agent and describe any
compensation received by them from us. Any initial public offering price and any discounts or concessions allowed or re-allowed or paid to dealers may be changed from time to time. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless otherwise specified in the applicable prospectus supplement, all securities we offer,
other than common stock, will be new issues of securities with no established trading market. Any underwriters may make a market in these securities, but will not be obligated to do so and may discontinue any market making at any time without
notice. Any common stock sold pursuant to a prospectus supplement will be listed for trading on The NASDAQ Capital Market or other principal market for our common stock. We may apply to list any series of preferred stock or warrants on an exchange,
but we are not obligated to do so. Therefore, there may not be liquidity or a trading market for any series of securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any
underwriter may engage in over-allotment transactions, stabilizing transactions, short-covering transactions and penalty bids in accordance with Regulation M under the Exchange Act. Over-allotment involves sales in excess of the offering size, which
create a short position. Stabilizing transactions permit bids to purchase the underlying security so long as the stabilizing bids do not exceed a specified maximum. Short covering transactions involve purchases of the securities in the open market
after the distribution is completed to cover short positions. Penalty bids permit the underwriters to reclaim a selling concession from a dealer when the securities originally sold by the dealer are purchased in a covering transaction to cover short
positions. Those activities may cause the price of the securities to be higher than it would otherwise be. If commenced, the underwriters may discontinue any of the activities at any time. We make no representation or prediction as to the direction
or magnitude of any effect that such transactions may have on the price of the securities. For a description of these activities, see the information under the heading &#147;Underwriting&#148; or &#147;Plan of Distribution&#148; in the applicable
prospectus supplement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Underwriters, broker-dealers or agents who may become involved in the sale of the common stock may engage in
transactions with and perform other services for us in the ordinary course of their business for which they receive compensation. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>E<A NAME="toc504779_10">
</A>XPERTS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">OUM&nbsp;&amp; Co. LLP, an independent registered public accounting firm, has audited our consolidated financial
statements included in our Annual Report on Form 10-K for the year ended December&nbsp;31, 2016, as set forth in their report, which is incorporated by reference in this prospectus and elsewhere in the registration statement. Our consolidated
financial statements are incorporated by reference in reliance on OUM&nbsp;&amp; Co. LLP&#146;s report, given on their authority as experts in accounting and auditing. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc504779_11"></A>LEGAL MATTERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The legality of the issuance of the securities being offered hereby and the binding nature of any warrants being offered hereby is being
passed upon by Gibson, Dunn&nbsp;&amp; Crutcher LLP, San Francisco, California. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc504779_12"></A>INFORMATION INCORPORATED BY REFERENCE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The SEC allows the Company to &#147;incorporate by reference&#148; the information that is filed by the Company with the SEC, which means that
the Company can disclose important information to you by referring you to those documents. The documents incorporated by reference are: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top">The Company&#146;s Annual Report on Form 10-K for the fiscal year ended December&nbsp;31, 2016; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top">Portions of our Definitive Proxy Statement on Schedule 14A filed with the SEC on April&nbsp;26, 2017 that have been incorporated by reference into our Annual Report on Form 10-K for the year ended December&nbsp;31,
2016; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top">The Company&#146;s Quarterly Report on Form 10-Q for the quarter ended March&nbsp;31, 2017; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top">The Company&#146;s Current Reports on Form 8-K filed with the SEC on January&nbsp;24, 2017,&nbsp;March&nbsp;17, 2017,&nbsp;April&nbsp;3, 2017, April&nbsp;24, 2017, and June&nbsp;13, 2017; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">5.</TD>
<TD ALIGN="left" VALIGN="top">The description of the Company&#146;s common stock contained in the registration statement on Form 8-A, as amended, filed with the SEC on January&nbsp;22, 2014 pursuant to Section&nbsp;12(b) of the Exchange Act,
including any amendment or report filed for the purpose of updating that description. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All documents we file with the SEC
pursuant to Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act, except as to any portion of any report or documents that is not deemed filed under such provisions, on or after the date of this prospectus until the earlier of the date on which
all of the securities registered hereunder have been sold or the registration statement of which this prospectus is a part has been withdrawn, shall be deemed incorporated by reference in this prospectus and to be a part of this prospectus from the
date of filing of those documents. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any statement contained in a document incorporated or deemed to be incorporated by reference herein
shall be deemed to be modified or superseded, for purposes of this prospectus, to the extent that a statement contained in or omitted from this prospectus, or in any other subsequently filed document that also is or is deemed to be incorporated by
reference herein, modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this prospectus. Nothing in this prospectus shall be deemed to
incorporate information furnished, but not filed, with the SEC pursuant to Item&nbsp;2.02 or Item&nbsp;7.01 of Form 8-K. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon written or
oral request, we will provide, without charge, to each person, including any beneficial owner, to whom a copy of this prospectus is delivered, upon such person&#146;s written or oral request, a copy of any and all of the information incorporated by
reference in this prospectus, other than exhibits to such documents, unless such exhibits are specifically incorporated by reference into the information that this prospectus incorporates. Requests should be directed to the Secretary at Heron
Therapeutics, Inc., 4242 Campus Point Court, Suite 200, San Diego, California 92121, telephone number (858)&nbsp;251-4400. You may also find these documents in the &#147;Investor Relations&#148; section of our website, <I>www.herontx.com</I>. The
information on our website is not incorporated into this prospectus. We have authorized no one to provide you with any information that differs from that contained in this prospectus. Accordingly, you should not rely on any information that is not
contained in this prospectus. You should not assume that the information in this prospectus is accurate as of any date other than the date of the front cover of this prospectus. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc504779_13"></A>WHERE YOU CAN FIND ADDITIONAL INFORMATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company is subject to the informational requirements of the Exchange Act, and in accordance therewith, files annual,&nbsp;quarterly and special reports,
proxy statements and other information with the SEC. You may read and copy any document filed by the Company at the SEC&#146;s Public Reference Room at 100 F Street, N.E., Washington, D.C. 20549. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Please call the SEC at 1-800-SEC-0330 for further information on the public reference room. The Company&#146;s filings with the SEC are also available to the public at the SEC&#146;s Internet web
site at <I>http://www.sec.gov</I>. Statements contained in this prospectus as to the contents of any contract or other document are not necessarily complete, and in each instance we refer you to the copy of the contract or document filed as an
exhibit to the registration statement, each such statement being qualified in all respects by such reference. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:2.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:2.00pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:36pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman" ALIGN="center"><B>9,677,419&nbsp;Shares </B></P>
<P STYLE="font-size:24pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g504779g04j69.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Common Stock </B></P> <P STYLE="font-size:120pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>PROSPECTUS&nbsp;SUPPLEMENT </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:100pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman" ALIGN="center"><B>Cantor
</B></P> <P STYLE="margin-top:130pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>December&nbsp;4, 2017 </B></P> <P STYLE="font-size:30pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:4.5pt;margin-top:0pt;margin-bottom:2pt;border-bottom:2.00pt solid #000000">&nbsp;</P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g504779g04j69.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g504779g04j69.jpg
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ML]/5-#514U1787:!EK*TM=8D)3,W0G%R<['!"3ABAI&AMM%#4E6%I</2_]H
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M9'9>3L"RID4U')O5$&7%BIXJG36;:Q\%WBIM?Q+M:%$+@:3O"V!JQ9J_=*W
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MH.+:EU/7ST.K]4\3>S]GJ,W-U]B+P5Z<HG>=E[DDSA9=U5&2:RPM<58MS<,
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M=G4S682I3B:!<P5>N0D'B$)1!!$+,Q7!P)-)S7R 1*^?AX6_V^'G-_EC#_\
M%GM5SEUJ^070K^)I?V3M37YLGY0;\^[(_P!<R^MC#FN.K)TXTU!WNEX]>MO>
MBM! [<K!$3?ZVA+NO-U4=]NN[7U[(#O9+!(@K.RRXX9'#'9]\S7IMF2A%%9R
M<P&+*MBR0TYV5U#W+L6R;,1:%N/LS,9'"7AFSB<BLA[#&Q5(H@&$'J>D(E;X
M'U",E22RP6;V[C<\H1N*D+"H_P &O(GP[=8HGNB5MB/,8+S\-D$OGUH&#X**
MQHGM=W?\4TH!0O(#&6#M9T\P8-$4WO%KR%,D[]0PGGD!1H._*JETL\KV>5BH
M=F3"R9@AQUWX,M.R9=W$.!:#MI[&ZKJ9?Z?,K[3WCV$ZYL;(O!6/OG ][3P%
MN8!8<\'(I !2,0/BU<8F/&.+!E\[M(AK[A!F6PW= (SU8)*Q7&9[1'()YDI^
M,8\0BDYF9[6VCGL'$GDDV[K'>G?/P2[/T_>:WL6@6;?5I*A;359)B3C"DXV!
MU\P\,ZIK/M@9()S.1I.)D&A92*,0Z%)!BELNL(RW3;$93!; Z\8O,4;..R%7
M U ?5MJ)30GT#<':41/D:SCUE-7)*:$P:S,)@I\FY;E6_N#85JF]5FNV^Z0:
MDX,)^KX_F.8\Q(9\B H@P+D2&"B8UL[<U@U:.J__ !M]#HWQV=?I30L5LL[:
MPTELJQ[%S9I"K#U!]EVPPM7AU1.(H:=L+:VQ4UI!"3,GI4]DQ3>1V\,X6[8/
M4K?K>HVX59]V,7BC7C:V.]&7:*X,Q7=:=#?%)%>8D_29&0[)B.SGNGNXB/;9
MP ;;QQX\+16X*TRSXI*A,Q+ 4'9VPQD3QX7/=W>?=QQY<S8!ROM2'3C33C33
MC35?]EZ'1MB\B^O_ "#+V6<)*4+2)NF&M6IJP[P$F.8Y=UYL"[;F=;(%>;^.
M;F,1J:^^A7P>C/ON/>5>QL&MOUM;ISD>GL8Q9JR&<#-3E/2B%BB"*,>CQ4\"
M1,9]"CZIZ0,QXD^IZOK1YN !FY*^XO2B@T42I>B^%$B43X_U3Q?$B8GZM];X
M<QZOQ^?E7CL?P<;*G>Q/8#L'ISR/[\ZWR'838$O>[57M10<_5DJ]_E9*4CH>
M5F:MM^K/V4>!<EY!$:1) M^QR86XP,,HI_"[$QO7/&HVYM_;V9Z;[?W*O;N/
M30J6,PY%N8\-2E,<I-K$6AK$^$KE@J.>[L""(NP>(Y9V)9/)9'(TMRY'&%D;
M!V'+I@Q/UQD8@9JMJEL+DR[9(?+F9B(YG76_(I]P?X;/O)_3^T/\1'.SX;-G
M_O([$_!L7_=[7Y]!.9]N<_\ ?;7Z1T^13[@_PV?>3^G]H?XB./ALV?\ O([$
M_!L7_=[3Z"<S[<Y_[[:_2.GR*?<'^&S[R?T_M#_$1Q\-FS_WD=B?@V+_ +O:
M?03F?;G/_?;7Z1T^13[@_P -GWD_I_:'^(CCX;-G_O([$_!L7_=[3Z"<S[<Y
M_P"^VOTCI\BGW!_AL^\G]/[0_P 1''PV;/\ WD=B?@V+_N]I]!.9]N<_]]M?
MI'5BI'02,(\C49Y"L[//3*QNFEZ@QJWXJCJ >96*>-F>S;<SV"4/>@[*_@_X
MOJ1G+>,>^?;9RFN1W^T>G#>GGO6OP6YJ,S[Z>EEX@E!++T?T3T?MD?J?'B>D
M1/GSV>7&I%.W@G<@[B]*+O&EZ'Z+X4=LQVE'B>-XG//GSV^'_+JPOE>:D>G&
MFG&FN,8&)(B%1\@*,< <,^&:$8PT4(8(4TI@D4H9]*V2!B&5K9?8>0MIUI:F
MW$J0K.,\@,UF#%F2V+(3 P*1,#&8(3 AF"$A*(D2B8F)B)B>=?A")#(E$$)1
M,$)1$B43Y3$Q/E,3'E,3Y3JF:>\-M1U[V('[*]$]^7/HY;9):\WZBT>J1MZT
MU>&<OX)]R)UI+SD#%1T60ZM]14"E\VN!N>Z&U:&J\F)[^]=".LUS([<+;.^\
M!2WS45$>]]^]:;1S5&>WM[QR:4/:QHQ P%CM"R<=X6G6E'X<0IFRTULE&3P.
M0?@G'^J$5U ^D^.>>V:IF "$S,\KB96/D2@44=TW'0K$P/#Q@]BD(V7G60!6
MIF3B(DB!BI&20PA)ID?"&3%A*B0B7\..CQQ$[,/"-+2PY(F*1E]=-/)).:59
M;4HEA2E3G#8<M4E,@#'@FL#3$>()@UTP<Q)0H(GMB9A!P PTA-D#$&0!*P(N
M/6D5D;9 9GS@98<Q'E)%\>JO^RWA=\>O9^4-M%ETJSK6^'N.$$7W1\DO64V\
M:ZO+SLF9#1@Y-%EI=TC]<NS$U4)*4>?QE;Q:_7<PNT=L]:NHFUU!5K9LLG0"
M($:&=7&41 1'$*!S2&^E,#ZL)1<4H1\H".(XBV4V3MW*F36T8JV"GF;%$O16
M27QR4@,37,YGSDS21S/G):C&)X4=MT=/P=I7RQ]]]=5EGU$@UZ3ODA: Q$-X
MREM&!XJR4J(SZK?J(^X0HV,I1C&4^KZB42@^MN(O?5,WTEV!D;,\^)85075,
MYGSF>YM:Z[SGS]9Q?'/[,S.+'8]NOZM'=VX*RH^M65@FC''Q>0,0'_@$:^1O
M@[N.Q$*C>POE%[\;>K#[:FBZRSL9^OQA33F<X>:<#L4CL*)]B^SZ&G4?!"LK
M^?*EYQG"$_J^N=/'3XNW>ENP,/:&8D+,XT;#0F/K2@ZR\<[D9\XGQHX_\]?A
M;$=9B0R.ZMP7%3'$JBS*QF)^.)AI60XF/*8[//4U.K7B6Z%=0I"/LFJ]%PLK
M?XU;+XFR]E%$[$NP9H^?2U)0IEC43$U*13\_I,ID-7'5X4I*\J3G..0G=75O
M?V\%LK97.O5CV1(GC,8(XZB8%'$K<%:!;;7_ -BZZR,?''&LYBMH;?PQ"VI0
M K \3%FS,V7Q,?$02WD$E_"@%SJR'E;:DNJ]>G'06,ZB;R[M[K!V<=>B.YVW
MF]L2%>+JH]?9U^^W:MHVCX##DF9Z778VLKV8\'[^\%#+]6';?]T])JFAK#WE
MO]N[\%LC",Q:Z [+P\XE=@+96"R S4Q=7QS42$Q6GC&0?AB;HY=(]_J1)1W"
M[>##W\Y>&T3YS=R+9+E4+BO,.MM[!*&'XD?X5(]TB'UG/'K<185RO-2+3C33
MC37 E8J+G8R0A)R- F8:7"*C96(E0QY&,DXXUE8QH$@ 6V\*:$6.XXP4*2TZ
MP0RXMIUM:%*3GL4UJ&K>AK$N28-4Y1DMJF 4$#%L"8,# H@@,9@A*(F)B8UQ
M, 8! P1,#&1,#&" Q*."$AF)@A*)F)B8F)CRG5'LCX&NME?[?Z=[5Z*N5CTE
M&:PVC!;8D-&1D0S9=:RMBAIF)EB/B>@R9C3==#SJ8E@64#$Q/Q+#;,>U"14/
M'QK$<J\5]>]S6-GYG:F>IULVW*8M^)7G6MFMDE5G)<H?3)!+ R)(\6249^ T
MIEDO:YC2;$%+8.,5F:66H.;1&K:"V5 0AM8V 8%/@]QB5:#[(@Q'Q C@8 0$
M('5Z/**U/-10OF_MK:XJ5GO-FZY2[%:J44=-S!@^T*&4\W&1[:GGWV@F'5D/
M+]DG*DL-H4XK/VN,9SR!97=F>P^/NY2[LYXTL>AMFPP,YBS*$)&2,A6,R93V
MQS Q$S/Q?'JO\MN[<&%Q][*W=F6!HX^NVU88&=Q3#A"8DC,5#,F4]L<]@\E]
MB.9UZBI[7V[9_BT<OKY(Q=>L/P,6N;>V91BO@Z&EO=GE2KL:.][Z1[F"1DM8
M+"?>GO9Y';3[92<<]U#/;AO>A-G:+44[GHS)LEF\8SP:UCL*7DD)\0_#4?B2
MH?7+CLCUIC7OQ^?W%>]!;.T&HIW/1F3:+.8MG@UK'84O) 3XA^&H_$E0^N7'
M9'K3&O8:9VO'[EIQ%PC8DR%&'M5OJV0SGV"'U/U"PGUX@O#@^,-X9,> 42RC
M./7;;<2A><JQG/,CMS/*W'CBR*:[*P#>R%'PVF)E)8^XZF;.0B([6$F3&/C@
M9B)\XUD=M9].Y<:623796 ;^1H>$TQ,I/'7'4S9W!$1VL),F,?&(E$3YQKD;
MHV>#IC5URVA)Q9<T#38M,H3% O,CEFH46,)AIA\C"F6U^L2E?K.8SCU4YQZ/
M3G'.>Y,VK;F#R.<<AEE6.1XYH40@QL2P%]HD<2(SR<3S,?%&N>YLZK;.!R6=
M>AEI6-1#SKJ(08V):M7:)G$B,\LB>9CXHG6/[YOJ7K6Q:7K"I:SD[[9KG1Y6
M^#MCV>!K8H,3$&@ EMODS>4,ND8=D1\H2VO&5)RKT)SZN?1B<KNJQ2S&-P>/
MPKLK=R.,?E @;U6D"J]=JE,@CL^J1]S@F(B?..?+RUB,MNRS2S.,P6.P;LM>
MR>+L988&]4I+37KM2ID$=G@2/N<'$#/G'/EY3QR/LF;V^C/(_G:UY_\ <<Y>
M_6ZO8IO\X,1_[ZY^_>Z_8AO\X<1_[ZXEVWQ9*M===:VB=32=HO-]I4O<WH5B
MWUN)'K[< N)9F(TF6D58CY!\0J50PA\-SV)/L5NL>LA2<\Z\GNJ[1R>'PM?
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M-G?W>U(O0:W[Z.=_&.S/[NZQWM2'FK+VTZ\AT_8\E6RUZ-V>0/=HN-J=D,E
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M"AAB;*I*&(<HHD&J:(&!#,3&H^DV2$V7W9UV[1)(*TQVI-2;%1?9J$):DH2
ME+K)5X2 @"I4-3P*9\I,488J(P_DUH%I9+C24-N>K$SNULUU+Q$XIR[R=OX#
M,1E;-4Q=6JOR3JBZM1EA<DKTLXKL9->#EHK&3(8B)XAYW:N<ZGX8L2]=].W=
MOYF,M9JF+ZM1^3=454J,L+DE>EG"&,FO!2T5#)D,1!<=YWC_  .UW^.S2/\
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9G\F&I]<M?5N:<::<::<::<::<::<::__V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
